JP5925015B2 - Absorbent articles - Google Patents

Description

  The present invention relates to absorbent articles such as sanitary napkins, panty liners, incontinence pads, and incontinence liners.

  An absorbent article obtained by applying a skin care composition to a top sheet of a main part is known as a conventional technique (for example, Patent Document 1). An apertured molded film is used for the top sheet of the absorbent article. Further, the absorbent article is provided with a flap formed by extending the top sheet in the width direction.

Special table 2003-510164 gazette

  When the wing part is folded in order to package an absorbent article as described in Patent Document 1, the skin care composition applied to the top sheet of the main body part is an open part of the top sheet in the folded wing part. It may penetrate into the wing through. In this case, the permeated skin care composition weakens the bonding between the top sheet and the back sheet in the wing part, and the top sheet may peel from the back sheet when the absorbent article is used for a long time.

  An object of the present invention is to provide an absorbent article in which a sheet constituting a wing part is prevented from peeling off when the composition applied to the top sheet penetrates into the wing part when the wing part is bent. To do.

The present invention employs the following configuration in order to solve the above problems.
That is, the present invention has a longitudinal direction and a width direction, and includes a main body part and a pair of wing parts extending in the width direction from both side edges of the main body part. A non-woven nonwoven top sheet, a liquid-impermeable back sheet provided on the clothing side, and an absorbent article provided with a liquid-retaining absorbent provided between the top sheet and the back sheet. The sheet is provided with a protrusion in an excretion opening contact area that contacts at least the wearer's excretion opening on the skin side surface, and the top sheet is a composition in which a predetermined composition is applied to at least the excretion opening contact area. A coating area is further provided.
Another aspect of the present invention includes a main body part and a pair of wing parts extending in the width direction from both side edges of the main body part, the main body part being a liquid-permeable member provided on the skin side. A non-woven nonwoven top sheet, a liquid-impermeable back sheet provided on the clothing side, and an absorbent article provided with a liquid-retaining absorbent provided between the top sheet and the back sheet. A compression part formed by embossing from the sheet to the inside of the absorbent body is provided in an excretion opening contact area that contacts at least the wearer's excretion opening on the skin side surface, and the top sheet is at least an excretion opening contact The area is provided with a composition application area where a predetermined composition is applied.

  ADVANTAGE OF THE INVENTION According to this invention, when the wing part is bent, it can suppress that the sheet | seat which comprises a wing part peels because the composition apply | coated to the top sheet osmose | permeates a wing part.

FIG. 1 is a partially broken plan view of an embodiment of an absorbent article of the present invention. FIG. 2 is a schematic cross-sectional view showing a cross section taken along line AA of FIG. Drawing 3 is a figure for explaining a projection and a crevice of a top sheet in an absorptive article of one embodiment of the present invention. FIG. 4 is a view for explaining a method of forming protrusions and recesses on the top sheet. Drawing 5 is a figure for explaining an absorptive article of one embodiment of the present invention by which a wing part was folded up for packaging. FIG. 6 is a perspective view of a packaged product including an absorbent article according to an embodiment of the present invention. FIG. 7 is a schematic cross-sectional view showing a cross section along the line DD in FIG. FIG. 8 is a diagram for explaining a protrusion, a recess, and an opening of a top sheet in a modification of the absorbent article according to one embodiment of the present invention. FIG. 9 is a view for explaining a method of forming the opening of the modified absorbent article according to the embodiment of the present invention. FIG. 10 is a view for explaining a protrusion of the top sheet in a modified example of the absorbent article according to one embodiment of the present invention. Drawing 11 is a figure for explaining the projection of a top sheet, a crevice, and an opening in a modification of an absorptive article of one embodiment of the present invention. Drawing 12 is a figure for explaining the modification of the absorptive article of one embodiment of the present invention. Drawing 13 is a figure for explaining the modification of the absorptive article of one embodiment of the present invention. FIG. 14 is an electron micrograph of the skin contact surface of the top sheet in a sanitary napkin in which the top sheet contains tri-C2L oil fatty acid glycerides. FIG. 15 is a photomicrograph of menstrual blood with or without a blood modifying agent. FIG. 16 is a diagram for explaining a method of measuring surface tension.

  Hereinafter, the present invention will be described with reference to the drawings, but the present invention is not limited to those described in the drawings.

  FIG. 1 is a partially broken plan view of an absorbent article according to an embodiment of the present invention, and FIG. 2 is a schematic cross-sectional view showing a cross section taken along line AA of FIG. The absorbent article 1 includes a liquid-permeable top sheet 2 provided on the skin side (skin contact side), a liquid-impermeable back sheet 3 provided on the clothing side (non-skin contact side), and a top sheet. A main body 10 having a liquid retaining absorbent 4 provided between the back sheet 3 and the back sheet 3 and a liquid impermeable side sheet 5 provided on both sides of the top sheet 2 in the width direction; And a pair of wings 6 provided with side sheets 5 and back sheets 3 extending in the width direction from both side edges.

  Reference numeral 61 denotes a root of the wing portion 6 (a boundary between the main body portion 10 and the wing portion 6). For example, a straight line connecting two points at which the width of the absorbent article 1 suddenly increases on both sides in the longitudinal direction of the wing portion 6 can be regarded as the root 61 of the wing portion 6. An adhesive portion 7 is provided on the clothing side surface of the wing portion 6. An adhesive portion 7 is also provided on the clothing side surface of the main body portion 10. In FIG. 1, the width direction of the absorbent article 1 is the X direction, and the longitudinal direction is the Y direction. Moreover, the planar direction of the absorbent article 1 is the XY direction. In addition, without providing the side seat | sheet 5, the top sheet 2 of the main-body part 10 may be extended in the width direction, and the wing part 6 may be provided with the top sheet 2 and the back seat | sheet 3. FIG.

  The shape of the main body 10 is not particularly limited as long as the shape matches the shape of the female body and the underwear, such as a rectangle, an ellipse, and an hourglass. The total length in the longitudinal direction of the outer shape of the main body 10 is preferably 100 to 500 mm, and more preferably 150 to 350 mm. Moreover, the total dimension of the width direction in the external shape of the main-body part 10 becomes like this. Preferably it is 30-200 mm, More preferably, it is 40-180 mm.

  The top sheet 2 moves body fluids such as urine and menstrual blood discharged from the wearer to the absorber 4. The top sheet 2 is wholly or partially liquid permeable, and the liquid permeable area of the top sheet 2 is a liquid permeable nonwoven fabric, a woven fabric, a resin film in which a large number of liquid permeable holes are formed, or a large number of meshes. It can be formed of a net-like sheet or the like.

  The top sheet 2 is preferably made from a nonwoven fabric. As a raw material of the nonwoven fabric used for the top sheet 2, either natural fibers or chemical fibers can be used. Examples of natural fibers include cellulose such as pulverized pulp and cotton. Examples of the chemical fiber include regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic chemical fiber, and thermoplastic hydrophobic chemical fiber subjected to hydrophilic treatment. Examples of thermoplastic hydrophobic chemical fibers include single fibers such as polyethylene (PE), polypropylene (PP), and polyethylene terephthalate (PET), fibers formed by graft polymerization of PE and PP, and composite fibers such as a core-sheath structure. It is done.

  When producing a nonwoven fabric to be used for the top sheet 2, web forming is performed by combining a dry method (a card method, a spunbond method, a melt blown method, an airlaid method, etc.) and a wet method, or a combination of a dry method and a wet method. Also good. Examples of the web bonding method for producing the nonwoven fabric used for the top sheet 2 include methods such as thermal bonding, needle punching, and chemical bonding, but are not limited to these methods. A spunlace formed into a sheet shape by the hydroentanglement method may be used for the top sheet 2.

  As the non-woven fabric fiber used for the top sheet 2, a core-sheath type in which the melting point of the core component is higher than that of the sheath component, an eccentric type of the core-sheath, or a side-by-side type composite fiber having different melting points of the left and right components may be used. In addition, hollow fibers, irregular fibers such as flat, Y-type and C-type, three-dimensional crimp fibers with latent crimp or actual crimp, and division by physical load such as water flow, heat or embossing Fibers such as fibers may be mixed in the nonwoven fabric used for the top sheet 2.

  Considering the penetration of the liquid and the touch, the fineness of the non-woven fabric used for the top sheet 2 is preferably 1.1 to 8.8 dtex.

  When using a hydrophobic synthetic fiber for the top sheet 2, considering the liquid penetration and rewet back of the top sheet 2, a hydrophilic agent or a water repellent is kneaded into the hydrophobic synthetic fiber, The hydrophobic synthetic fiber may be coated with a liquid agent or the like. Further, hydrophilicity may be imparted to the hydrophobic synthetic fiber by corona treatment or plasma treatment. Thereby, when the blood modifying agent described later is lipophilic, hydrophilic portions and lipophilic portions coexist sparsely in the blood modifying agent application region 18, and the hydrophilicity of body fluid (for example, menstrual blood) Both the sex component (mainly plasma) and the lipophilic component (mainly blood cells) quickly migrate from the topsheet 2 to the absorber 4.

  In order to improve the concealability of the top sheet 2, the nonwoven fabric fibers used in the top sheet 2 may contain an inorganic filler such as titanium oxide, barium sulfate, and calcium carbonate. When the nonwoven fabric fiber is a core-sheath type composite fiber, an inorganic filler may be contained only in the core, or only in the sheath.

  A blood modifying agent application region 18 to which a blood modifying agent described later is applied is provided at least in the excretion opening contact region 16 of the top sheet 2. Here, the excretion opening contact area 16 is preferably 50 to 200 mm, more preferably 70 to 150 mm in the length in the longitudinal direction centering on the position where the excretion opening of the wearer's body fluid comes into contact. The length in the width direction is preferably 10 to 80 mm, more preferably 20 to 50 mm. In order to wrap the absorbent article 1, when the pair of wings 6 are folded inward in the width direction so that the outer edges 62 of the pair of wings 6 are in contact with each other, the blood modifying agent application region 18 becomes large. Part or all of the part is covered with the folded wing 6 (see FIGS. 5 and 7).

  The top sheet 2 extends at least in the excretory opening contact region 16 in the longitudinal direction (Y direction) and intersects with the longitudinal direction (Y direction), for example, the protrusions 21 and the recesses aligned in the width direction (X direction). 22. With reference to FIG. 3, the protrusion 21 and the recessed part 22 provided in the top sheet 2 are demonstrated in detail. FIG. 3 is an enlarged perspective view of the protrusion 21 and the recess 22 of the top sheet 2. In addition, if the direction where the protrusion 21 and the recessed part 22 are extended is a predetermined direction, it will not be limited to a longitudinal direction.

  As shown in FIG. 3, the top sheet 2 extends in the longitudinal direction (Y direction) and has a plurality of protrusions 21 arranged in a direction intersecting the longitudinal direction (Y direction), for example, in the width direction (X direction). And a recess 22. The shape of the cross section of the protrusion 21 is, for example, a substantially U shape. In addition to the U-shape, the substantially U-shape includes a shape that becomes U-shaped when a modification such as rounding a corner or changing a straight line to a curve is applied. For example, the substantially U shape includes a V shape, an M shape, and a trapezoid. The cross-sectional shape of the protrusion 21 may be an Ω shape.

  The thickness of the thickest portion of the protrusion 21 is preferably 0.3 to 15 mm, and more preferably 0.5 to 5 mm. Moreover, the length of the width direction (X direction) of a protrusion becomes like this. Preferably it is 0.5-30 mm, More preferably, it is 1.0-10 mm. The distance (pitch) between the vertices in the width direction (X direction) of the adjacent protrusions is preferably 0.5 to 30 mm, more preferably 3 to 10 mm. The thickness of the thinnest portion of the recess 22 is preferably 1 to 50%, and more preferably 5 to 20%, with respect to the thickness of the thickest portion of the protrusion 21. The length in the width direction (X direction) of the recess 22 is preferably 0.1 to 30 mm, more preferably 0.5 to 10 mm.

The fiber density of the central portion 23 of the protrusion 21 is preferably lower than the fiber density of the side portion 24 and / or the recess 22 of the protrusion 21. For example, the fiber density of the central portion 23 and the recess 22 of the projection 21 is 0.005~0.20g / cm ^3, preferably 0.007~0.07g / cm ^3. The fiber density at each location of the topsheet can be measured, for example, as follows. A top sheet having a predetermined machine direction (MD) length in which the protrusions 21 and the recesses 22 are formed is sampled. Then, using a microscope or the like, a micrograph of the cross section of the top sheet in the width direction (CD) is taken, and the cross-sectional area of the central portion of the protrusion 21, the cross-sectional area of the side portion of the protrusion, The cross-sectional area is measured using an image processing device. Next, the top sheet is cooled using liquid nitrogen or the like, and the central part, the side part of the protruding part, and the concave part of the cooled top sheet are separated from the top sheet. Then, the weights of the central part of the separated protrusions, the side parts of the protrusions, and the recesses are measured. Finally, by dividing the measured weights of the central part of the protrusion, the side part of the protrusion and the concave part by the above-mentioned machine direction (MD) length and the cross-sectional area, the central part of the protrusion of the top sheet Fiber density, fiber density of the side part of the protrusion, and fiber density of the concave part can be calculated. In addition, the magnitude relationship between the fiber density of the central portion 23 of the protrusion 21 and the fiber density of the side portion 24 and / or the recess 22 of the protrusion 21 is based on the density of fibers in the micrograph of the cross section of the top sheet. I can judge. The fiber density code 25 indicates the fibers of the topsheet 2.

  Next, with reference to FIG. 4, a method for forming the protrusions 21 and the recesses 22 in the top sheet 2 will be described. As shown in FIG. 4, the web 120 used as the material of the top sheet 2 is disposed on the mesh support member 130 and moved in the machine direction (MD). The web 120 moves between the blowing unit 140 and the suction unit 150. The blowing unit 140 jets the gas 141 onto the web 120, and the suction unit 150 sucks the gas 141 jetted from the blowing unit 140. The gas 141 injected from the blowing unit 140 scrapes the fibers of the web 120. Thereby, the groove | channel 122 corresponding to the recessed part 22 of the top sheet 2 is formed in the web 120. FIG. Further, the fibers scraped by the gas 141 ejected from the blowing unit 140 gather on both sides of the groove 122. Thereby, protrusions 121 corresponding to the protrusions 21 of the top sheet 2 are formed on both sides of the groove 122.

  The net-like support member 130 is a net-like support body having air permeability. For example, weaving resinous yarns such as polyester, polyphenylene sulfide, nylon, and conductive monofilaments, or metallic yarns such as stainless steel, copper, and aluminum in plain weave, twill weave, satin weave, double weave, spiral weave, etc. The breathable net thus prepared can be used as the mesh-like support member 130.

  The blowing unit 140 includes a plurality of blowing ports (not shown) arranged in the width direction. Thereby, the blowing unit 140 can inject a plurality of gases 141 arranged in the width direction (CD) onto the web 120. Moreover, the gas 141 injected from the blowing unit 140 is, for example, normal temperature or heated nitrogen, air, and water vapor. The gas 141 ejected from the blowing unit 140 may include liquid or solid fine particles.

  By reciprocating the blowing portion 140 in the width direction (CD), a meandering (wavy, zigzag) groove portion can be formed in the web. Moreover, a discontinuous groove | channel can be formed in a web by injecting the gas 141 to the web 120 intermittently from the blowing part 140. FIG.

  Since the scraped fibers are concentrated on the side surface of the protrusion 121, the fiber density on the side surface of the protrusion 121 is increased. Moreover, since the gas 141 which ejected from the blowing part 140 hits the groove | channel 122 and a web is compressed, the fiber density in the groove | channel 122 becomes high. On the other hand, in the central portion of the protrusion 121, the scraped fibers gather but are not compressed by the gas 141 ejected from the blowing portion 140, so the fiber density in the central portion of the protrusion 121 is low. Accordingly, the fiber density of the central portion 23 of the protrusion 21 is lower than the fiber density of the side portion 24 and / or the recess 22 of the protrusion 21.

  The back sheet 3 shown in FIGS. 1 and 2 prevents body fluid absorbed by the absorbent body 4 from leaking out. A material that does not transmit body fluid is used for the backsheet 3. For example, a hydrophobic nonwoven fabric, a water-impermeable plastic film such as polyethylene and polypropylene, or a laminate sheet of a nonwoven fabric and a water-impermeable plastic film is used as the back sheet 3. Alternatively, a spunbond / meltblown / spunbond (SMS) fiber nonwoven fabric in which a melt-blown nonwoven fabric having high water resistance is sandwiched between strong spunbond nonwoven fabrics may be used as the back sheet 3. The use of a breathable material that does not allow body fluid to pass through can be used to reduce stuffiness when worn. The back sheet 3 is bonded to the top sheet 2 using an adhesive such as a hot melt adhesive.

  The absorber 4 absorbs and holds the body fluid. It is preferable that the absorber 4 is bulky, does not easily lose its shape, and has little chemical stimulation. For example, as the absorbent body 4, a composite absorbent body made of fluffy pulp or air laid nonwoven fabric and a super absorbent polymer (SAP) is used. This composite absorbent body may be covered with a liquid-permeable material such as a tissue.

Moreover, you may use artificial cellulose fibers, such as a chemical pulp, a cellulose fiber, rayon, and an acetate, for example instead of the fluffy pulp of the said composite absorber. The basis weight of absorbent fibers such as pulp in the composite absorbent is preferably 100 g / m ² or more and 800 g / m ² or less, and the mass ratio of the superabsorbent polymer in the composite absorbent is absorbent. The fiber content is preferably 10% or more and 65% or less with 100%. The basis weight of the liquid-permeable material such as a tissue covering the composite mixture is preferably 12 g / m ² or more and 30 g / m ² or less.

  As the airlaid nonwoven fabric of the composite mixture, for example, a nonwoven fabric obtained by thermally fusing pulp and synthetic fiber or a nonwoven fabric obtained by fixing pulp and synthetic fiber with a binder can be used.

  The superabsorbent polymer of the composite absorbent has a three-dimensional network structure in which water-soluble polymers are appropriately crosslinked. This absorbent polymer absorbs 30 to 60 times as much water as the volume of the absorbent polymer before absorbing water. However, this absorbent polymer is essentially water insoluble. Moreover, even if this absorptive polymer is applied some pressure, it does not water the water once absorbed. As the absorbent polymer, for example, a starch-based, acrylic acid-based or amino acid-based particulate or fibrous polymer is used.

  Although the shape and structure of the absorber 4 can be changed as necessary, the total absorption amount of the absorber 4 needs to correspond to the design insertion amount and the desired application as the absorbent article 1. Further, the size and absorption capacity of the absorber 4 vary depending on the application.

  The absorbent body 4 is bonded to the top sheet 2 using a hot melt adhesive. Thereby, it can suppress that the top sheet 2 peels from the absorber 4. FIG.

  The side sheet 5 prevents body fluid from leaking to the outside in the width direction of the absorbent article 1 through the surface and / or inside of the top sheet 2. The side sheet 5 preferably has hydrophobicity or water repellency. For the side sheet 5, for example, a spunbond nonwoven fabric or an SMS nonwoven fabric is used. Moreover, since the side sheet | seat 5 contacts with a wearer's skin, it is preferable to use the air through nonwoven fabric for the side sheet | seat 5 which can reduce the rub irritation | stimulation to skin. In addition, the absorbent article 1 does not need to have the side sheet 5.

  As described above, the wing portion 6 is provided in the absorbent article 1 in order to stably fix the absorbent article 1 to the underwear. The absorbent article 1 can be stably fixed to the undergarment by bending the wing part 6 to the outer surface side of the undergarment and then sticking it to the crotch region of the undergarment via the adhesive part 7. Moreover, it can suppress that the main-body part 10 slip | deviates during wear by sticking the adhesion part 7 provided in the main-body part 10 to the crotch area of underwear.

  The adhesive part 7 of the absorbent article 1 shown in FIG. 2 fixes the absorbent article 1 to the crotch area of the underwear. As the pressure-sensitive adhesive that forms the pressure-sensitive adhesive portion 7, for example, a styrene polymer, a tackifier, or a plasticizer, which is a main component, is preferably used. Examples of the styrenic polymer include styrene-ethylene-butylene-styrene block copolymers, styrene-butylene polymers, styrene-butylene-styrene block copolymers, and styrene-isobutylene-styrene copolymers. Only one of them may be used, or two or more polymer blends may be used. Among these, a styrene-ethylene-butylene-styrene block copolymer is preferable in terms of good thermal stability.

  As the tackifier and plasticizer, those that are solid at room temperature can be preferably used. Examples of the tackifier include C5 petroleum resins, C9 petroleum resins, dicyclopentadiene petroleum resins, and rosin petroleum resins. Polyterpene resin, terpene phenol resin, etc., and examples of the plasticizer include monomer plasticizers such as trifresil phosphate, dibutyl phthalate and dioctyl phthalate, and polymer plasticizers such as vinyl polymers and polyesters. It is done.

  As shown in FIGS. 1 and 2, the top sheet 2 and the absorbent body 4 have pressing grooves 8 that are formed by compressing in the thickness direction by embossing and extend from the top sheet 2 to the inside of the absorbent body 4. The compressed groove 8 suppresses diffusion of body fluid discharged to the central portion of the absorbent article 1 (portion that contacts the wearer's body fluid excretion opening) in the width direction (X direction). Moreover, it can suppress that the top sheet 2 peels from the absorber 4 by this. The compressed groove 8 surrounds the central portion of the absorbent article 1 and has a continuous substantially annular shape. In addition, the pressing groove 8 surrounding the center part of the absorbent article 1 may be partially interrupted. That is, the pressing groove 8 may have a discontinuous substantially annular shape.

  Further, by compressing and joining the top sheet 2 to the back sheet 3 by heat embossing, seal portions 9 are formed at the edge portions on both sides in the longitudinal direction of the main body portion 10 and the edge portions on the outer side in the width direction of the wing portions 6. The Thereby, the top sheet 2 can be prevented from being peeled off from the back sheet 3. Furthermore, the back sheet 3 and the side sheet 5 are joined by the seal part 9 of the wing part 6 by heat embossing. Thereby, the side sheet 5 can be prevented from peeling off from the back sheet 3.

Next, the above blood modifying agent will be described in detail. The blood modifying agent is about 0.00 to about 0.05 g of IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and 100 g of water at 25 ° C. Water solubility.

IOB (Inorganic Organic Balance) is an index indicating a balance between hydrophilicity and lipophilicity. In the present specification, the following formula by Oda et al.
IOB = value calculated by inorganic value / organic value.

  The inorganic value and the organic value are represented by Fujita Minoru, “Prediction of organic compounds and conceptual diagram of organic compounds” in the field of chemistry Vol. 11, no. 10 (1957) p. 719-725). The organic and inorganic values of the main groups by Fujita are summarized in Table 1 below.

For example, in the case of an ester of tetradecanoic acid having 14 carbon atoms and dodecyl alcohol having 12 carbon atoms, the organic value is 520 (CH ₂ , 20 × 26), and the inorganic value is 60 (—COOR, 60 × 1), so that IOB = 0.12.

  In the blood modifying agent, the IOB is about 0.00 to about 0.60, preferably about 0.00 to about 0.50, and preferably about 0.00 to about 0.40. More preferably, and more preferably from about 0 to about 0.30. This is because the lower the IOB, the higher the organicity and the higher the affinity with blood cells.

  In the present specification, the “melting point” means a peak top temperature of an endothermic peak when changing from a solid state to a liquid state when measured with a differential scanning calorimeter at a temperature rising rate of 10 ° C./min. The melting point can be measured, for example, using a DSC-60 type DSC measuring apparatus manufactured by Shimadzu Corporation.

  The blood modifying agent may be liquid or solid at room temperature, as long as it has a melting point of about 45 ° C. or lower, that is, whether the melting point is about 25 ° C. or more, or less than about 25 ° C. Well and can have a melting point of, for example, about −5 ° C., about −20 ° C. The reason why the melting point of the blood modifying agent is about 45 ° C. or less will be described later.

  The blood modifying agent has a lower melting point, but preferably has a low vapor pressure. The blood pressure of the blood modifying agent is preferably about 0.00 to about 0.01 Pa, more preferably about 0.000 to about 0.001 Pa at 1 atmosphere and 25 ° C., and about 0 More preferably, it is 0.000 to about 0.0001 Pa. Considering that the absorbent article of the present disclosure is used in contact with the human body, the vapor pressure is preferably about 0.00 to about 0.01 Pa at 1 atmosphere and 40 ° C., and about 0.000 to More preferably, it is about 0.001 Pa, and more preferably about 0.0000 to about 0.0001 Pa. This is because if the vapor pressure is high, vaporization may occur during storage, and problems such as a decrease in the amount of blood modifying agent and odor when worn may occur.

  Further, the melting point of the blood modifying agent can be properly used according to the climate, the length of wearing time, and the like. For example, in an area where the average temperature is about 10 ° C. or less, even when the menstrual blood is excreted and then cooled by the ambient temperature by adopting a blood modifying agent having a melting point of about 10 ° C. or less. It is considered that the blood modifying agent can stably modify blood. Further, when the absorbent article is used for a long time, the melting point of the blood modifying agent is preferably higher in the range of 45 ° C. or lower. This is because the blood modifying agent is difficult to move even when it is worn for a long time, and is hardly affected by sweat, friction at the time of wearing, and the like.

  The water solubility of 0.00-0.05 g was obtained by adding 0.05 g of sample to 100 g of deionized water at 25 ° C., allowing to stand for 24 hours, and after 24 hours, stirring lightly as necessary. Then, it can be measured by visually evaluating whether or not the sample is dissolved. In the present specification, regarding dissolution in water, “dissolution” includes a case where the sample is completely dissolved in deionized water to form a uniform mixture and a case where the sample is completely emulsified. “Complete” means that there is no lump of sample in deionized water.

  In this technical field, the surface of a top sheet is coated with a surfactant for the purpose of changing the surface tension of blood and the like to absorb blood rapidly. However, since surfactants generally have high water solubility, top sheets coated with surfactants are well-suited to hydrophilic components (blood plasma, etc.) in blood, but rather leave blood on the top sheet. There is a tendency to work. Since the blood modifying agent has low water solubility, it is considered that blood can be quickly transferred to the absorbent body without remaining on the top sheet, unlike conventionally known surfactants.

  In the present specification, the solubility in 100 g of water at 25 ° C. may be simply referred to as “water solubility”.

In this specification, “weight average molecular weight” refers to a polydisperse compound (for example, a compound produced by sequential polymerization, an ester produced from a plurality of fatty acids and a plurality of aliphatic monohydric alcohols), A concept including one compound (for example, one fatty acid and one ester formed from one aliphatic monohydric alcohol), and N _i molecules having a molecular weight M _i (i = 1 or i = 1) , 2 ...), the following formula:
M _w = ΣN _i M _i ² / ΣN _i M _i
Means M _w obtained by

In this specification, a weight average molecular weight means the value of polystyrene conversion calculated | required by gel permeation chromatography (GPC). Examples of GPC measurement conditions include the following.
Model: Hitachi High-Technologies Corporation High-Performance Liquid Chromatogram Lachrom Elite
Column: SHODEX KF-801, KF-803 and KF-804 manufactured by Showa Denko K.K.
Eluent: THF
Flow rate: 1.0 mL / min Driving amount: 100 μL
Detection: RI (differential refractometer)
In addition, the weight average molecular weight described in the Example of this specification is measured on the said conditions.

The blood modifying agent is preferably the following (i) to (iii),
(I) hydrocarbons,
(Ii) from (ii-1) a hydrocarbon moiety and (ii-2) a carbonyl group (—CO—) and an oxy group (—O—) inserted between the C—C single bonds of the hydrocarbon moiety. A compound having one or more of the same or different groups selected from the group consisting of: (iii) (iii-1) a hydrocarbon moiety, and (iii-2) a CC single bond of the hydrocarbon moiety One or a plurality of the same or different groups selected from the group consisting of a carbonyl group (—CO—) and an oxy group (—O—), and (iii-3) A compound having one or a plurality of the same or different groups selected from the group consisting of a carboxyl group (—COOH) and a hydroxyl group (—OH), which replaces a hydrogen atom;
As well as any combination thereof.

  In the present specification, “hydrocarbon” means a compound composed of carbon and hydrogen, and is a chain hydrocarbon, for example, a paraffinic hydrocarbon (also referred to as an alkane, which does not include a double bond and a triple bond). , Olefinic hydrocarbons (including one double bond, also referred to as alkene), acetylenic hydrocarbons (including one triple bond, also referred to as alkyne), and the group consisting of double and triple bonds And hydrocarbons containing two or more bonds selected from the above, and cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.

  The hydrocarbons are preferably chain hydrocarbons and alicyclic hydrocarbons, more preferably chain hydrocarbons, two paraffin hydrocarbons, olefin hydrocarbons, and two double bonds. More preferred are hydrocarbons (not including triple bonds), and more preferred are paraffinic hydrocarbons. The chain hydrocarbon includes a straight chain hydrocarbon and a branched chain hydrocarbon.

  In the compounds (ii) and (iii), when two or more oxy groups (—O—) are inserted, the oxy groups (—O—) are not adjacent to each other. Therefore, the compounds (ii) and (iii) do not include compounds having a continuous oxy group (so-called peroxides).

  In the compound (iii) above, at least one hydrogen atom in the hydrocarbon moiety is substituted with a hydroxyl group (-) than in a compound in which at least one hydrogen atom in the hydrocarbon moiety is substituted with a carboxyl group (-COOH). Compounds substituted with OH) are preferred. As shown in Table 1, since the carboxyl group binds to menstrual metals and the like, and the inorganic value increases significantly from 150 to 400 or more, the blood modifying agent having a carboxyl group is used at the time of use. This is because the value of IOB exceeds about 0.60, and the affinity with blood cells may be reduced.

The blood modifying agent is more preferably the following (i ′) to (iii ′),
(I ′) hydrocarbon,
(Ii ′) (ii′-1) a hydrocarbon moiety and (ii′-2) a carbonyl bond (—CO—), an ester bond (—COO) inserted between the C—C single bonds of the hydrocarbon moiety. -), A carbonate bond (-OCOO-), and an ether bond (-O-), one or more compounds having the same or different bonds, and (iii ') (iii'- 1) a hydrocarbon moiety and (iii′-2) a carbonyl bond (—CO—), an ester bond (—COO—), a carbonate bond (—OCOO) inserted between the C—C single bonds of the hydrocarbon moiety. -), And one or a plurality of the same or different bonds selected from the group consisting of ether bonds (-O-), and (iii'-3) a carboxyl group that replaces the hydrogen atom of the hydrocarbon moiety ( -COOH ) And a hydroxyl group (—OH), one or more compounds having the same or different groups,
As well as any combination thereof.

  In the compounds (ii ′) and (iii ′) above, when two or more identical or different bonds are inserted, that is, a carbonyl bond (—CO—), an ester bond (—COO—), a carbonate bond (— When two or more identical or different bonds selected from OCOO-) and ether bonds (-O-) are inserted, the bonds are not adjacent, and there is at least carbon between each bond. One atom intervenes.

  More preferably, the blood modifying agent is more preferably about 1.8 or less carbonyl bonds (—CO—) and 2 or less ester bonds (—COO—) per 10 carbon atoms in the hydrocarbon moiety. About 1.5 or less carbonate bonds (—OCOO—), about 6 or less ether bonds (—O—), about 0.8 or less carboxyl groups (—COOH), and / or hydroxyl groups (—OH) ) In a compound having about 1.2 or less.

The blood modifying agent is more preferably the following (A) to (F),
(A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain An ester with a compound having one carboxyl group for substituting a hydrogen atom in the hydrocarbon moiety,
(B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain An ether with a compound having one hydroxyl group replacing a hydrogen atom of the hydrocarbon moiety,
(C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon moiety and a hydroxyl group that replaces a hydrogen atom of the chain hydrocarbon moiety,
(D) an ether bond (—O—), a carbonyl bond (—CO—), an ester bond (—COO—) inserted between the chain hydrocarbon moiety and the CC single bond of the chain hydrocarbon moiety. And a compound having any one bond selected from the group consisting of a carbonate bond (—OCOO—),
(E) polyoxy C ₂ -C ₆ alkylene glycol, or an alkyl ester or alkyl ether thereof, and (F) a chain hydrocarbon,
As well as any combination thereof. Hereinafter, the blood modifying agent according to (A) to (F) will be described in detail.

[(A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and Esters with compounds having one carboxyl group replacing a hydrogen atom of a chain hydrocarbon moiety]
(A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain As long as an ester with a compound having one carboxyl group that substitutes a hydrogen atom in the hydrocarbon moiety (hereinafter sometimes referred to as “compound (A)”) has the above-mentioned IOB, melting point and water solubility, , Not all hydroxyl groups may be esterified.

(A1) As a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety (hereinafter sometimes referred to as “compound (A1)”) A chain hydrocarbon tetraol, such as an alkanetetraol, such as pentaerythritol, a chain hydrocarbon triol, such as an alkanetriol, such as glycerin, and a chain hydrocarbon diol, such as an alkanediol, such as, for example, Glycol.
Examples of the compound (A2) having a chain hydrocarbon moiety and one carboxyl group that replaces the hydrogen atom of the chain hydrocarbon moiety (hereinafter sometimes referred to as “compound (A2)”) include: , A compound in which one hydrogen atom on a hydrocarbon is substituted with one carboxyl group (—COOH), for example, a fatty acid.
Examples of the compound (A) include (a ₁ ) an ester of a chain hydrocarbon tetraol and at least one fatty acid, (a ₂ ) an ester of a chain hydrocarbon triol and at least one fatty acid, and (a ₃ ) Esters of chain hydrocarbon diols with at least one fatty acid.

[Ester of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid]
Examples of the ester of the chain hydrocarbon tetraol and at least one fatty acid include the following formula (1):
Tetraesters of pentaerythritol and fatty acids of the following formula (2):
Triesters of pentaerythritol and fatty acids of the following formula (3):
Diester of pentaerythritol and fatty acid of the following formula (4):
And monoesters of pentaerythritol and fatty acids.
(In the formula, R ^{1 to} R ⁴ are each a chain hydrocarbon)

As the fatty acid (R ¹ COOH, R ² COOH, R ³ COOH, and R ⁴ COOH) constituting the ester of pentaerythritol and fatty acid, the ester of pentaerythritol and fatty acid has the above-mentioned IOB, melting point and water solubility. as long as it satisfies the requirement is not particularly limited, for example, saturated fatty acids, for example, saturated fatty acids C ₂ -C _30, for example, acetic acid (C ₂₎ (C ₂ indicates the number of carbon atoms, R ¹ C, Corresponding to the carbon number of R ² C, R ³ C or R ⁴ C, the same shall apply hereinafter), propanoic acid (C ₃ ), butanoic acid (C ₄ ) and isomers thereof such as 2-methylpropanoic acid (C ₄ ), pentanoic acid (C ₅₎ and isomers thereof such as 2-methylbutanoic acid (C _5), 2,2-dimethyl propanoic acid (C _5), hexanoic acid (C _6), heptanoic acid (C ₇₎ Octanoic acid (C ₈₎ and isomers thereof, e.g., 2-ethylhexanoic acid (C _8), nonanoic acid (C _9), decanoic acid (C _10), dodecanoic acid (C _12), tetradecanoic acid (C ₁₄₎ Hexadecanoic acid (C ₁₆ ), heptadecanoic acid (C ₁₇ ), octadecanoic acid (C ₁₈ ), eicosanoic acid (C ₂₀ ), docosanoic acid (C ₂₂ ), tetracosanoic acid (C ₂₄ ), hexacosanoic acid (C ₂₆ ), Examples include octacosanoic acid (C ₂₈ ), triacontanoic acid (C ₃₀ ), and the like, and isomers thereof (except those described above).

The fatty acid can also be an unsaturated fatty acid. Examples of the unsaturated fatty acid include C _{3 to} C ₂₀ unsaturated fatty acids such as monounsaturated fatty acids such as crotonic acid (C ₄ ), myristoleic acid (C ₁₄ ), palmitoleic acid (C ₁₆ ), Oleic acid (C ₁₈ ), elaidic acid (C ₁₈ ), vaccenic acid (C ₁₈ ), gadoleic acid (C ₂₀ ), eicosenoic acid (C ₂₀ ), etc., diunsaturated fatty acids such as linoleic acid (C ₁₈ ), Triunsaturated fatty acids such as eicosadienoic acid (C ₂₀ ), such as linolenic acid such as α-linolenic acid (C ₁₈ ) and γ-linolenic acid (C ₁₈ ), pinolenic acid (C ₁₈ ), eleostearic acid, For example, α-eleostearic acid (C ₁₈ ) and β-eleostearic acid (C ₁₈ ), mead acid (C ₂₀ ), dihomo-γ-linolenic acid (C ₂₀ ), eicosatrienoic acid (C ₂₀ ) Etc., tetraunsaturated Fatty acid, e.g., stearidonic acid (C _20), arachidonic acid (C _20), eicosatetraenoic acid (C _20), etc., penta-unsaturated fatty acids, for example, bosseopentaenoic acid (C _18), eicosapentaenoic acid (C ₂₀ ) And the like, as well as these partial hydrogenated products.

  The ester of pentaerythritol and fatty acid is an ester of pentaerythritol and a fatty acid derived from a saturated fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid, considering the possibility of modification by oxidation or the like. preferable. The ester of pentaerythritol and fatty acid is preferably a diester, triester or tetraester, more preferably a triester or tetraester, in order to reduce IOB and make it more hydrophobic. And tetraesters are more preferred.

In the tetraester of pentaerythritol and fatty acid, the total number of carbon atoms of the fatty acid constituting the tetraester of pentaerythritol and fatty acid, that is, in the above formula (1), R ¹ C, R ² C, R ³ C and When the total number of carbon atoms in the R ⁴ C portion is 15, IOB is 0.60. Therefore, in the tetraester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbons is about 15 or more. In the tetraester of pentaerythritol and fatty acid, for example, pentaerythritol, hexanoic acid (C ₆ ), heptanoic acid (C ₇ ), octanoic acid (C ₈ ), for example, 2-ethylhexanoic acid (C ₈ ), Examples thereof include tetraesters with nonanoic acid (C ₉ ), decanoic acid (C ₁₀ ) and / or dodecanoic acid (C ₁₂ ).

In the triester of pentaerythritol and fatty acid, the total number of carbon atoms of the fatty acid constituting the triester of pentaerythritol and fatty acid, that is, in the above formula (2), R ¹ C, R ² C and R ³ C moieties When the total number of carbon atoms is 19, IOB is 0.58. Therefore, in the triester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 19 or more.

In the diester of pentaerythritol and fatty acid, the total number of carbon atoms of the fatty acid constituting the diester of pentaerythritol and fatty acid, that is, the total number of carbon atoms of the R ¹ C and R ² C moieties in the above formula (3) is In the case of 22, the IOB is 0.59. Therefore, in the diester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 22 or more.

In the monoester of pentaerythritol and fatty acid, the number of carbons of the fatty acid constituting the monoester of pentaerythritol and fatty acid, that is, in the above formula (4), the IOB is 25 when the carbon number of the R ¹ C portion is 25. 0.60. Therefore, in the monoester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the fatty acid has about 25 or more carbon atoms. In the above calculation, the influence of double bonds, triple bonds, iso branches, and tert branches is not taken into consideration.

  As a commercial item of the ester of the said pentaerythritol and a fatty acid, Unistar H-408BRS, H-2408BRS-22 (mixture), etc. (above, NOF Corporation make) are mentioned.

[Ester of (a ₂ ) chain hydrocarbon triol and at least one fatty acid]
Examples of the ester of the chain hydrocarbon triol and at least one fatty acid include the following formula (5):
Triester of glycerin and fatty acid of the following formula (6):
A diester of glycerin and a fatty acid, and the following formula (7):
(Wherein R ^{5 to} R ⁷ are each a chain hydrocarbon)
And monoesters of glycerin and fatty acids.

As the fatty acid (R ⁵ COOH, R ⁶ COOH and R ⁷ COOH) constituting the ester of the glycerin and the fatty acid, as long as the ester of glycerin and the fatty acid satisfies the requirements for the IOB, melting point and water solubility, In particular, the fatty acids listed in “esters of (a ₁ ) chain hydrocarbon tetraols and at least one fatty acid”, that is, saturated fatty acids and unsaturated fatty acids, are exemplified and modified by oxidation or the like. In consideration of the possibility, it is preferable to use an ester of glycerin and a fatty acid derived from a saturated fatty acid, that is, an ester of glycerin and a saturated fatty acid.

  The ester of glycerin and fatty acid is preferably a diester or triester and more preferably a triester in order to reduce IOB and make it more hydrophobic.

The triester of glycerin and a fatty acid is also called a triglyceride. For example, triester of glycerin and octanoic acid (C ₈ ), triester of glycerin and decanoic acid (C ₁₀ ), glycerin and dodecanoic acid (C ₁₂ ) And triesters of glycerin with 2 or 3 fatty acids, and mixtures thereof.

Examples of the triesters of glycerin and two or more fatty acids include triesters of glycerin and octanoic acid (C ₈ ) and decanoic acid (C ₁₀ ), glycerin, octanoic acid (C ₈ ), and decane. Acid (C ₁₀ ) and Dodecanoic acid (C ₁₂ ) Triester, Glycerin, Octanoic acid (C ₈ ), Decanoic acid (C ₁₀ ), Dodecanoic acid (C ₁₂ ), Tetradecanoic acid (C ₁₄ ), Hexadecanoic acid Examples thereof include triesters with (C ₁₆ ) and octadecanoic acid (C ₁₈ ).

As the triester of glycerin and fatty acid, the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid, that is, R ⁵ C in formula (5) in order to make the melting point about 45 ° C. or less. , R ⁶ C and R ⁷ C moieties preferably have a total carbon number of about 40 or less.

In the triester of glycerin and fatty acid, the total number of carbon atoms of the fatty acid constituting the triester of glycerin and fatty acid, that is, in the formula (5), R ⁵ C, R ⁶ C and R ⁷ C moieties When the total number of carbon atoms is 12, the IOB is 0.60. Accordingly, in the triester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 12 or more. The triester of glycerin and a fatty acid is a so-called fat and is a component that can constitute a human body, and thus is preferable from the viewpoint of safety.

  Commercial products of the above-mentioned triester of glycerin and fatty acid include tricoconut oil fatty acid glyceride, NA36, panacet 800, panacet 800B and panacet 810S, and tri-C2L oil fatty acid glyceride and tri-CL oil fatty acid glyceride (above, manufactured by NOF Corporation). ) And the like.

The diester of glycerin and fatty acid is also called diglyceride. For example, diester of glycerin and decanoic acid (C ₁₀ ), diester of glycerin and dodecanoic acid (C ₁₂ ), glycerin and hexadecanoic acid (C ₁₆ ) Examples include diesters, diesters of glycerin and two fatty acids, and mixtures thereof.

In the diester of glycerin and fatty acid, the total number of carbon atoms of the fatty acid constituting the diester of glycerin and fatty acid, that is, the total number of carbon atoms of the R ⁵ C and R ⁶ C moieties in the formula (6) is 16. The IOB is 0.58. Therefore, in the diester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbon atoms of the fatty acid is about 16 or more.

The monoester of glycerin and fatty acid is also referred to as monoglyceride, and examples thereof include glycerin icosanoic acid (C ₂₀ ) monoester, glycerin docosanoic acid (C ₂₂ ) monoester, and the like. In the monoester of glycerin and fatty acid, the number of carbon atoms of the fatty acid constituting the monoester of glycerin and fatty acid, that is, when the carbon number of the R ⁵ C moiety in the formula (7) is 19, the IOB is 0.59. It becomes. Therefore, in the monoester of the glycerin and the fatty acid, when the carbon number of the fatty acid is about 19 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.

[Ester of (a ₃ ) chain hydrocarbon diol and at least one fatty acid]
Examples of the ester of the chain hydrocarbon diol and at least one fatty acid include C _{2 to} C ₆ chain hydrocarbon diols such as C _{2 to} C ₆ glycols such as ethylene glycol, propylene glycol, and butylene. Examples thereof include monoesters or diesters of glycol, pentylene glycol or hexylene glycol and a fatty acid.

Specifically, as the ester of the chain hydrocarbon diol and at least one fatty acid, for example, the following formula (8):
R ⁸ COOC _k H _2k OCOR ⁹ (8)
(Wherein k is an integer from 2 to 6 and R ⁸ and R ⁹ are each a chain hydrocarbon)
A diester of a C ₂ -C ₆ glycol with a fatty acid and the following formula (9):
R ⁸ COOC _k H _2k OH (9)
(Wherein k is an integer from 2 to 6 and R ⁸ is a chain hydrocarbon)
And monoesters of C ₂ -C ₆ glycols and fatty acids.

In the ester of C ₂ -C ₆ glycol and fatty acid, the fatty acid to be esterified (corresponding to R ⁸ COOH and R ⁹ COOH in formula (8) and formula (9)) is C ₂ -C ₆ glycol. And an ester of a fatty acid satisfying the above requirements for IOB, melting point and water solubility, for example, “(a ₁ ) ester of a chain hydrocarbon tetraol and at least one fatty acid” The fatty acids listed in the above, that is, saturated fatty acids and unsaturated fatty acids are mentioned, and saturated fatty acids are preferred in consideration of the possibility of modification by oxidation or the like.

In the diester of butylene glycol (k = 4) and the fatty acid represented by the formula (8), when the total number of carbon atoms in the R ⁸ C and R ⁹ C moieties is 6, IOB is 0.60. Therefore, in the diester of butylene glycol (k = 4) and a fatty acid represented by the formula (8), when the total number of carbon atoms is about 6 or more, the IOB has a requirement of about 0.00 to about 0.60. Fulfill. Moreover, in the monoester of ethylene glycol (k = 2) and a fatty acid represented by the formula (9), when the carbon number of the R ⁸ C portion is 12, the IOB is 0.57. Therefore, in the monoester of ethylene glycol (k = 2) and a fatty acid represented by the formula (9), the requirement that the IOB is about 0.00 to about 0.60 when the carbon number of the fatty acid is about 12 or more. Meet.

The ester of a C ₂ -C ₆ glycol and fatty acids, in consideration of the potential for degradation by oxidation and the like, derived from saturated fatty acids, esters of C ₂ -C ₆ glycol and fatty acid, Nachi Suwa, C ₂ it is preferable -C ₆ glycol and an ester of saturated fatty acids.

As the ester of a C ₂ -C ₆ glycol and fatty acid, to reduce the IOB, in order to more hydrophobic, from large glycol carbon number, esters of glycols and fatty acids, for example, butylene glycol It is preferably an ester of glycol and fatty acid derived from pentylene glycol or hexylene glycol.

Furthermore, the ester of the C ₂ -C ₆ glycol and the fatty acid is preferably a diester in order to reduce IOB and make it more hydrophobic. Examples of commercial products of esters of the C ₂ -C ₆ glycols with fatty acids, for example, COMPOL BL, COMPOL BS (products of NOF Corporation) and the like.

[(B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the above Ether with a compound having one hydroxyl group replacing a hydrogen atom of a chain hydrocarbon moiety]
(B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain As long as it has the above-mentioned IOB, melting point, and water solubility, an ether with a compound having one hydroxyl group replacing a hydrogen atom of the hydrocarbon-like hydrocarbon moiety (hereinafter sometimes referred to as “compound (B)”) , All the hydroxyl groups may not be etherified.

(B1) Compounds having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety are listed as compounds (A1) in “Compound (A)”. For example, pentaerythritol, glycerin, and glycol.
Examples of the compound (B2) having a chain hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the chain hydrocarbon moiety (hereinafter sometimes referred to as “compound (B2)”) include: , Compounds in which one hydrogen atom of a hydrocarbon is replaced by one hydroxyl group (—OH), such as aliphatic monohydric alcohols such as saturated aliphatic monohydric alcohols and unsaturated aliphatic monohydric alcohols Is mentioned.

Examples of the saturated aliphatic monohydric alcohol include C _{1 to} C ₂₀ saturated aliphatic monohydric alcohols such as methyl alcohol (C ₁ ) (C ₁ represents the number of carbon atoms, the same shall apply hereinafter), ethyl alcohol ( C _2), propyl alcohol (C ₃₎ and isomers thereof, for example, isopropyl alcohol (C _3), butyl alcohol (C ₄₎ and isomers thereof, for example, sec- butyl alcohol (C ₄₎ and tert- butyl alcohol (C ₄ ), pentyl alcohol (C ₅ ), hexyl alcohol (C ₆ ), heptyl alcohol (C ₇ ), octyl alcohol (C ₈ ) and isomers thereof such as 2-ethylhexyl alcohol (C ₈ ), nonyl alcohol (C ₉ ), decyl alcohol (C ₁₀ ), dodecyl alcohol (C ₁₂ ), tetradecyl al Cole (C ₁₄ ), Hexadecyl alcohol (C ₁₆ ), Hepradecyl alcohol (C ₁₇ ), Octadecyl alcohol (C ₁₈ ), and Eicosyl alcohol (C ₂₀ ) and their unlisted isomers It is done.

  Examples of the unsaturated aliphatic monohydric alcohol include those obtained by substituting one of the C—C single bonds of the saturated aliphatic monohydric alcohol with a C═C double bond, such as oleyl alcohol. It is commercially available from Shin Nippon Rika Co., Ltd. under the names of the Rica Coal series and the Angelo All series.

Examples of the compound (B) include (b ₁ ) ethers of a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, such as monoether, diether, triether and tetraether, preferably diether, triether. Ethers and tetraethers, more preferably triethers and tetraethers, and even more preferably tetraethers, ethers of (b ₂ ) chain hydrocarbon triols and at least one aliphatic monohydric alcohol, such as monoethers, diethers and triether, preferably diethers and triethers and more preferably tri-ether, and (b ₃₎ a chain hydrocarbon diol and at least one aliphatic monohydric ether alcohols, for example, mono- and diethers and, Mashiku diethers.

Examples of the ether of the chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol include the following formulas (10) to (13):
(In the formula, R ^{10 to} R ¹³ are each a chain hydrocarbon.)
And tetraethers, triethers, diethers and monoethers of pentaerythritol and aliphatic monohydric alcohols.

Examples of the ether of the chain hydrocarbon triol and at least one aliphatic monohydric alcohol include the following formulas (14) to (16):
(In the formula, R ^{14 to} R ¹⁶ are each a chain hydrocarbon.)
And triethers, diethers and monoethers of glycerin and aliphatic monohydric alcohols.

Examples of the ether of the chain hydrocarbon diol and at least one aliphatic monohydric alcohol include the following formula (17):
R ¹⁷ OC _n H _2n OR ¹⁸ (17)
(Wherein n is an integer from 2 to 6 and R ¹⁷ and R ¹⁸ are each a chain hydrocarbon)
A diether of a C ₂ -C ₆ glycol and an aliphatic monohydric alcohol, and the following formula (18):
R ¹⁷ OC _n H _2n OH (18)
(Wherein n is an integer from 2 to 6 and R ¹⁷ is a chain hydrocarbon)
And a monoether of a C ₂ -C ₆ glycol and an aliphatic monohydric alcohol.

In the tetraether of pentaerythritol and aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the tetraether of pentaerythritol and aliphatic monohydric alcohol, that is, in the above formula (10), When the total number of carbon atoms in R ¹⁰ , R ¹¹ , R ¹² and R ¹³ is 4, IOB is 0.44. Therefore, in the tetraether of pentaerythritol and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 4 or more, the IOB is about 0.00 to about 0.60. Fulfill.

In the triether of pentaerythritol and aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of pentaerythritol and aliphatic monohydric alcohol, that is, in the above formula (11), When the total number of carbon atoms in R ¹⁰ , R ¹¹ and R ¹² is 9, IOB is 0.57. Therefore, in the above-mentioned triether of pentaerythritol and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 9 or more, the IOB is about 0.00 to about 0.60. Fulfill.

In the diether of pentaerythritol and aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of pentaerythritol and aliphatic monohydric alcohol, that is, in the formula (12), R ¹⁰ When the total number of carbon atoms in the R ¹¹ portion is 15, the IOB is 0.60. Therefore, in the diether of pentaerythritol and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 15 or more, IOB satisfies the requirement of about 0.00 to about 0.60. .

In the monoether of pentaerythritol and aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of pentaerythritol and aliphatic monohydric alcohol, that is, in the above formula (13), R ¹⁰ When the number of carbon atoms in the portion is 22, the IOB is 0.59. Accordingly, in the monoether of pentaerythritol and aliphatic monohydric alcohol, when the aliphatic monohydric alcohol has about 22 or more carbon atoms, the IOB satisfies the requirement of about 0.00 to about 0.60.

In the triether of glycerin and aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the triether of glycerin and aliphatic monohydric alcohol, that is, in the formula (14), R ^When the total number of carbon atoms in the ¹⁴ , R ¹⁵ and R ¹⁶ parts is 3, the IOB is 0.50. Therefore, in the triether of glycerin and aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 3 or more, IOB satisfies the requirement of about 0.00 to about 0.60. .

In the diether of glycerin and aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of glycerin and aliphatic monohydric alcohol, that is, in the formula (15), R ¹⁴ and R ¹⁵ When the total number of carbon atoms in the portion is 9, the IOB is 0.58. Therefore, in the diether of the glycerin and the aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 9 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.

In the monoether of glycerin and aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of glycerin and aliphatic monohydric alcohol, that is, the carbon of R ¹⁴ moiety in the formula (16). When the number is 16, the IOB is 0.58. Therefore, in the monoether of the glycerin and the aliphatic monohydric alcohol, when the aliphatic monohydric alcohol has about 16 or more carbon atoms, the IOB satisfies the requirement of about 0.00 to about 0.60.

In the diether of butylene glycol (n = 4) and aliphatic monohydric alcohol represented by the formula (17), when the total number of carbon atoms in the R ¹⁷ and R ¹⁸ parts is 2, the IOB is 0.33. . Therefore, in the diether of butylene glycol (n = 4) and the aliphatic monohydric alcohol represented by the formula (17), when the total number of carbon atoms of the aliphatic monohydric alcohol is 2 or more, the IOB is about 0.00 Meet the requirement of ~ 0.60. Further, in the monoether of ethylene glycol (n = 2) and aliphatic monohydric alcohol represented by the formula (18), when the number of carbon atoms in the R ¹⁷ portion is 8, the IOB is 0.60. Therefore, in the monoether of ethylene glycol (n = 2) and the aliphatic monohydric alcohol represented by the formula (18), when the aliphatic monohydric alcohol has about 8 or more carbon atoms, the IOB is about 0. Satisfies the requirement of 00 to about 0.60.

  The compound (B) can be produced by dehydrating and condensing the compound (B1) and the compound (B2) in the presence of an acid catalyst.

[(C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety; (C2) Ester of a compound having a chain hydrocarbon moiety and one hydroxyl group substituting a hydrogen atom of the chain hydrocarbon moiety]
(C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety; C2) An ester (hereinafter sometimes referred to as “compound (C)”) of a compound having a chain hydrocarbon moiety and one hydroxyl group that substitutes a hydrogen atom of the chain hydrocarbon moiety, As long as it has the above-mentioned IOB, melting point and water solubility, not all carboxyl groups need to be esterified.

  (C1) Carboxylic acids, hydroxy acids, alkoxy acids or oxo acids (hereinafter referred to as “compounds”) containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups that replace the hydrogen atoms of the chain hydrocarbon moiety. C1) "may be referred to as, for example, a chain hydrocarbon carboxylic acid having 2 to 4 carboxyl groups, such as a chain hydrocarbon dicarboxylic acid, such as an alkanedicarboxylic acid, such as ethanedioic acid. , Propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, nonanedioic acid and decanedioic acid, chain hydrocarbon tricarboxylic acids such as alkanetricarboxylic acid such as propane Acid, butanetriacid, pentanetriacid, hexanetriacid, heptanetriacid, octanetriacid, nonanetriacid and decanetriacid, and chain And hydrocarbon hydrocarbon tetracarboxylic acids such as alkanetetracarboxylic acids such as butanetetraacid, pentanetetraacid, hexanetetraacid, heptanetetraacid, octanetetraacid, nonanetetraacid and decanetetraacid.

  Further, the compound (C1) includes a chain hydrocarbon hydroxy acid having 2 to 4 carboxyl groups, for example, a chain chain having 2 to 4 carboxyl groups such as malic acid, tartaric acid, citric acid, isocitric acid and the like. Hydrocarbon alkoxy acids such as O-acetylcitric acid and chain hydrocarbon oxoacids having 2 to 4 carboxyl groups are included. (C2) Examples of the compound having a chain hydrocarbon moiety and one hydroxyl group substituting a hydrogen atom of the chain hydrocarbon moiety include those listed in the section of “Compound (B)”, for example, An aliphatic monohydric alcohol is mentioned.

Examples of the compound (C) include (c ₁ ) an ester of a linear hydrocarbon tetracarboxylic acid having 4 carboxyl groups, a hydroxy acid, an alkoxy acid or an oxo acid and at least one aliphatic monohydric alcohol, for example, Monoesters, diesters, triesters and tetraesters, preferably diesters, triesters and tetraesters, more preferably triesters and tetraesters, and even more preferably tetraesters, (c ₂ ) a chain having three carboxyl groups Esters of hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxo acids with at least one aliphatic monohydric alcohol, such as monoesters, diesters and triesters, preferably diesters and triesters, and more preferably triesters Ester, and (c ₃₎ a chain hydrocarbon dicarboxylic acids having two carboxyl groups, hydroxy acids, esters of alkoxy acids or oxoacids, and at least one aliphatic monohydric alcohol, for example, mono- and diesters, Preferably diester is mentioned. Examples of compound (C) include dioctyl adipate, tributyl O-acetylcitrate and the like, and are commercially available.

[(D) an ether bond (—O—), a carbonyl bond (—CO—), an ester bond (—COO) inserted between a chain hydrocarbon moiety and a CC single bond of the chain hydrocarbon moiety. And a compound having any one bond selected from the group consisting of a carbonate bond (—OCOO—)]
(D) an ether bond (—O—), a carbonyl bond (—CO—), an ester bond (—COO—) inserted between the chain hydrocarbon moiety and the CC single bond of the chain hydrocarbon moiety. And a compound having any one bond selected from the group consisting of carbonate bonds (—OCOO—) (hereinafter sometimes referred to as “compound (D)”), (d ₁ ) aliphatic Examples include ethers of monohydric alcohols and aliphatic monohydric alcohols, (d ₂ ) dialkyl ketones, (d ₃ ) esters of fatty acids and aliphatic monohydric alcohols, and (d ₄ ) dialkyl carbonates.

[(D ₁ ) Ether of aliphatic monohydric alcohol and aliphatic monohydric alcohol]
Examples of the ether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol include the following formula (19):
R ¹⁹ OR ²⁰ (19)
(In the formula, R ¹⁹ and R ²⁰ are each a chain hydrocarbon)
The compound which has is mentioned.

As the aliphatic monohydric alcohol constituting the ether (corresponding to R ¹⁹ OH and R ²⁰ OH in the formula (19)), the ether satisfies the requirements of the IOB, melting point and water solubility. There is no particular limitation, and examples thereof include aliphatic monohydric alcohols listed in the section of “Compound (B)”.

In the ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the ether, that is, the carbon number of R ¹⁹ and R ²⁰ in the above formula (19). Since the IOB is 0.50 when the sum of the two is 2, the IOB requirement is satisfied if the total number of carbon atoms is about 2 or more. However, when the total number of carbon atoms is about 6, the water solubility is as high as about 2 g, which is problematic from the viewpoint of vapor pressure. In order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total number of carbon atoms is preferably about 8 or more.

[(D ₂ ) dialkylketone]
As the dialkyl ketone, the following formula (20):
R ²¹ COR ²² (20)
(Wherein R ²¹ and R ²² are each an alkyl group)
The compound which has is mentioned.

In the dialkyl ketone, since the IOB is 0.54 when the total number of carbon atoms of R ²¹ and R ²² is 5, the above IOB requirement is satisfied if the total number of carbon atoms is about 5 or more. However, when the total number of carbon atoms is about 5, the water solubility is as high as about 2 g. Therefore, in order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total number of carbon atoms is preferably about 8 or more. In consideration of the vapor pressure, the carbon number is preferably about 10 or more, and more preferably about 12 or more. When the total number of carbon atoms is about 8, for example, 5-nonanone has a melting point of about −50 ° C. and a vapor pressure of about 230 Pa at 20 ° C. In addition to being commercially available, the dialkyl ketone can be obtained by a known method, for example, by oxidizing a secondary alcohol with chromic acid or the like.

[(D ₃ ) ester of fatty acid and aliphatic monohydric alcohol]
Examples of the ester of the fatty acid and the aliphatic monohydric alcohol include the following formula (21):
R ²³ COOR ²⁴ (21)
(Wherein R ²³ and R ²⁴ are each a chain hydrocarbon)
The compound which has is mentioned.

Examples of the fatty acid constituting the ester (corresponding to R ²³ COOH in the formula (21)) are listed in “(a ₁ ) ester of chain hydrocarbon tetraol and at least one fatty acid”. Fatty acids, that is, saturated fatty acids or unsaturated fatty acids can be mentioned, and saturated fatty acids are preferred in consideration of the possibility of modification by oxidation or the like. Examples of the aliphatic monohydric alcohol constituting the ester (corresponding to R ²⁴ OH in formula (21)) include the aliphatic monohydric alcohols listed in the section “Compound (B)”.

In the ester of the fatty acid and the aliphatic monohydric alcohol, the total number of carbon atoms of the fatty acid and the aliphatic monohydric alcohol, that is, the total number of carbon atoms in the R ²³ C and R ²⁴ portions in the formula (21) is 5 In this case, since the IOB is 0.60, the above IOB requirement is satisfied when the total number of carbon atoms in the R ²³ C and R ²⁴ portions is about 5 or more. However, for example, butyl acetate having a total carbon number of 6 has a high vapor pressure of over 2,000 Pa. Therefore, considering the vapor pressure, the total number of carbon atoms is preferably about 12 or more. When the total number of carbon atoms is about 11 or more, the water solubility can satisfy the requirement of about 0.00 to about 0.05 g.

Examples of the ester of the fatty acid and the aliphatic monohydric alcohol include, for example, an ester of dodecanoic acid (C ₁₂ ) and dodecyl alcohol (C ₁₂ ), tetradecanoic acid (C ₁₄ ), and dodecyl alcohol (C ₁₂ ). Examples of commercially available esters of fatty acids and aliphatic monohydric alcohols include Electol WE20 and Electol WE40 (manufactured by NOF Corporation).

[(D ₄ ) dialkyl carbonate]
As the dialkyl carbonate, the following formula (22):
R ²⁵ OC (= O) OR ²⁶ (22)
(Wherein R ²⁵ and R ²⁶ are each an alkyl group)
The compound which has is mentioned.

In the above dialkyl carbonate, since the IOB is 0.57 when the total number of carbon atoms of R ²⁵ and R ²⁶ is 6, if the total number of carbon atoms of R ²⁵ and R ²⁶ is about 6 or more, Satisfy requirements. In consideration of water solubility, the total number of carbon atoms of R ²⁵ and R ²⁶ is preferably about 7 or more, and more preferably about 9 or more. In addition to being commercially available, the dialkyl carbonate can be synthesized by a reaction between phosgene and an alcohol, a reaction between a chlorinated formate and an alcohol or an alcoholate, and a reaction between silver carbonate and an alkyl iodide.

[(E) polyoxy C ₂ -C ₆ alkylene glycol, or ester or ether thereof]
Examples of the polyoxy C ₂ -C ₆ alkylene glycol, or an ester or ether thereof (hereinafter sometimes referred to as compound (E)) include (e ₁ ) polyoxy C ₂ -C ₆ alkylene glycol, (e ₂ ) polyoxy C esters of ₂ -C ₆ alkylene glycol and at least one fatty acid, (e ₃₎ polyoxy C ₂ -C ₆ ethers of alkylene glycol and at least one aliphatic monohydric alcohol, (e ₄₎ polyoxy C ₂ -C ₆ Esters of alkylene glycol with chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid, and (e ₅ ) polyoxy C ₂ -C ₆ alkylene glycol with chain hydrocarbon tetra All, chain hydrocarbon triols, or ethers with chain hydrocarbon diols That. This will be described below.

[(E ₁ ) polyoxy C ₂ -C ₆ alkylene glycol]
The polyoxy C ₂ -C ₆ alkylene glycol is selected from the group consisting of i) oxy C ₂ -C ₆ alkylene skeleton, that is, oxyethylene skeleton, oxypropylene skeleton, oxybutylene skeleton, oxypentylene skeleton, and oxyhexylene skeleton. A homopolymer having any one skeleton selected and having hydroxy groups at both ends; ii) a block copolymer having two or more skeletons selected from the above group and having hydroxy groups at both ends; Or iii) means a random copolymer having two or more skeletons selected from the above group and having hydroxy groups at both ends.

The oxy C ₂ -C ₆ alkylene skeleton is preferably an oxypropylene skeleton, an oxybutylene skeleton, an oxypentylene skeleton, or an oxyhexylene skeleton from the viewpoint of lowering the IOB of the polyoxy C ₂ -C ₆ alkylene glycol. , An oxybutylene skeleton, an oxypentylene skeleton, or an oxyhexylene skeleton is more preferable.

The polyoxy C ₂ -C ₆ alkylene glycol is represented by the following formula (23):
_{HO- (C m H 2m O)} n -H (23)
(In the formula, m is an integer of 2 to 6)
Can be represented by:

The present inventors have confirmed that polyethylene glycol (corresponding to a homopolymer of m = 2 in the formula (23)) is about 0 when n ≧ 45 (weight average molecular weight is more than about 2,000). Although satisfying the IOB requirement of 0.00 to about 0.60, the water solubility requirement was not met even when the weight average molecular weight exceeded about 4,000. Thus, (e ₁ ) polyoxy C ₂ -C ₆ alkylene glycol is considered not to include a homopolymer of ethylene glycol, which is a block copolymer or random copolymer with other glycols (e ₁ ) It should be included in the polyoxy C ₂ -C ₆ alkylene glycol.

  Thus, the homopolymer of formula (23) may include a homopolymer of propylene glycol, butylene glycol, pentylene glycol or hexylene glycol. From the above, in formula (23), m is about 3 to about 6, more preferably about 4 to about 6, and n is 2 or more.

In the above formula (23), the value of n is such that the poly C ₂ -C ₆ alkylene glycol has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and 100 g of water at 25 ° C. A value having a water solubility of about 0.00 to about 0.05 g. For example, when Formula (23) is polypropylene glycol (homopolymer of m = 3), when n = 12, IOB is 0.58. Therefore, when Formula (23) is polypropylene glycol (m = 3 homopolymer), the above IOB requirement is satisfied when m ≧ about 12. Further, when the formula (21) is polybutylene glycol (m = 4 homopolymer), when n = 7, the IOB is 0.57. Therefore, when Formula (23) is polybutylene glycol (m = 4 homopolymer), the above IOB requirement is satisfied when n ≧ about 7.

From the viewpoint of IOB, melting point and water solubility, the weight average molecular weight of the polyoxy C ₂ -C ₆ alkylene glycol is preferably about 200 to about 10,000, more preferably about 250 to about 8,000, and more preferably, It is in the range of about 250 to about 5,000. Further, from the viewpoint of IOB, melting point and water solubility, the weight average molecular weight of the poly C ₃ alkylene glycol, ie, polypropylene glycol, is preferably about 1,000 to about 10,000, more preferably about 3,000 to about 8 , And more preferably in the range of about 4,000 to about 5,000. This is because, when the weight average molecular weight is less than about 1,000, the water solubility does not satisfy the requirement, and the higher the weight average molecular weight, the more the absorber transfer speed and the whiteness of the top sheet tend to be improved.

Examples of commercial products of polyoxy C ₂ -C ₆ alkylene glycol, e.g., UNIOL (TM) D-1000, D-1200 , D-2000, D-3000, D-4000, PB-500, PB-700, PB -1000 and PB-2000 (above, manufactured by NOF Corporation).

[(E ₂ ) ester of polyoxy C ₂ -C ₆ alkylene glycol and at least one fatty acid]
Examples of the ester of the polyoxy C ₂ -C ₆ alkylene glycol and at least one fatty acid include the OH terminal of the polyoxy C ₂ -C ₆ alkylene glycol described in the section “(e ₁ ) polyoxy C ₂ -C ₆ alkylene glycol”. One or both of them are esterified with a fatty acid, that is, monoesters and diesters.

Examples of the fatty acid to be esterified in the ester of polyoxy C ₂ -C ₆ alkylene glycol and at least one fatty acid are listed in “Ester of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid”. Fatty acids, that is, saturated fatty acids or unsaturated fatty acids, and saturated fatty acids are preferred in consideration of the possibility of modification by oxidation or the like. Examples of commercial products of esters of polyoxy C ₂ -C ₆ alkylene glycols with fatty acids, for example, Will Bright cp9 (NOF Corporation) and the like.

[(E ₃ ) ether of polyoxy C ₂ -C ₆ alkylene glycol and at least one aliphatic monohydric alcohol]
The ethers of polyoxy C ₂ -C ₆ alkylene glycol and at least one aliphatic monohydric alcohol, "(e ₁₎ polyoxy C ₂ -C ₆ alkylene glycol" polyoxy C ₂ -C ₆ alkylene which is described in the Mention may be made of those in which one or both of the OH ends of the glycol are etherified with an aliphatic monohydric alcohol, ie monoethers and diethers. Examples of the aliphatic monohydric alcohol to be etherified in the ether of polyoxy C ₂ -C ₆ alkylene glycol and at least one aliphatic monohydric alcohol include, for example, the aliphatic enumerated in the section of “Compound (B)”. A monohydric alcohol is mentioned.

[Ester of (e ₄ ) polyoxy C ₂ -C ₆ alkylene glycol and chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid]
As an ester of the above polyoxy C ₂ -C ₆ alkylene glycol and a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid, as a polyoxy C ₂ -C ₆ alkylene glycol to be esterified is polyoxy C ₂ -C ₆ alkylene glycol is described in the section "(e ₁₎ polyoxy C ₂ -C ₆ alkylene glycol" may be mentioned. Examples of the chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, and chain hydrocarbon dicarboxylic acid to be esterified include those described in the section of “Compound (C)”.

Esters of the above polyoxy C ₂ -C ₆ alkylene glycol and chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid are commercially available, and chain hydrocarbon tetracarboxylic acid. It can be produced by polycondensing a C ₂ -C ₆ alkylene glycol to an acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid under known conditions.

[(E ₅ ) ether of polyoxy C ₂ -C ₆ alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon diol]
In the ether of the above polyoxy C ₂ -C ₆ alkylene glycol and a chain hydrocarbon tetraol, a chain hydrocarbon triol, or a chain hydrocarbon diol, the polyoxy C ₂ -C ₆ alkylene glycol to be etherified includes: Examples thereof include the polyoxy C ₂ -C ₆ alkylene glycol described in the section “(e ₁ ) polyoxy C ₂ -C ₆ alkylene glycol”. The chain hydrocarbon tetraol, chain hydrocarbon triol, and chain hydrocarbon diol to be etherified include those described in the section of “Compound (A)”, for example, pentaerythritol, glycerin, and glycol. Is mentioned.

Examples of commercially available ethers of the above polyoxy C ₂ -C ₆ alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon diol include, for example, Unilube (trademark) 5TP-300KB, and Uniol (trademark) TG-3000 and TG-4000 (made by NOF Corporation) are mentioned. Unilube (trademark) 5TP-300KB is a compound obtained by polycondensation of 1 mol of pentaerythritol with 65 mol of propylene glycol and 5 mol of ethylene glycol. Its IOB is 0.39, and its melting point is less than 45 ° C. Yes, and the water solubility was less than 0.05 g.

  Uniol ™ TG-3000 is a compound obtained by polycondensation of 1 mol of glycerin and 50 mol of propylene glycol, its IOB is 0.42, its melting point is less than 45 ° C, and its water solubility is 0.05 g. And the weight average molecular weight was about 3,000. Uniol ™ TG-4000 is a compound obtained by polycondensation of 70 mol of propylene glycol with 1 mol of glycerin, its IOB is 0.40, its melting point is less than 45 ° C., and its water solubility is 0.05 g. And the weight average molecular weight was about 4,000.

The ether of the polyoxy C ₂ -C ₆ alkylene glycol and the chain hydrocarbon tetraol, the chain hydrocarbon triol, or the chain hydrocarbon diol is also a chain hydrocarbon tetraol, a chain hydrocarbon triol, or It can be produced by adding C ₂ -C ₆ alkylene oxide to a chain hydrocarbon diol under known conditions.

[(F) chain hydrocarbon]
Since the chain hydrocarbon has an inorganic value of 0, the IOB is 0.00 and the water solubility is approximately 0 g. Therefore, if the melting point is about 45 ° C. or less, the blood It can be included in the modifier. Examples of the chain hydrocarbon include (f ₁ ) chain alkanes such as straight chain alkanes and branched chain alkanes. For example, in the case of straight chain alkanes, the melting point is about 45 ° C. or less. In general, those having 22 or less carbon atoms are included. Moreover, when the vapor pressure is taken into consideration, those having 13 or more carbon atoms are generally included. In the case of a branched chain alkane, the melting point may be lower at the same number of carbons than that of a straight chain alkane. As a commercial item of the above-mentioned hydrocarbon, for example, Pearl Ream 6 (NOF Corporation) can be mentioned.

  The blood modifying agent will be discussed in detail in conjunction with the examples, but it has been found that it has at least an action of lowering blood viscosity and surface tension. Compared with normal blood, menstrual blood to be absorbed by the absorbent article contains proteins such as the endometrial wall. Cheap. Therefore, menstrual blood to be absorbed by the absorbent article tends to have a high viscosity, and when the top sheet is a nonwoven fabric or a woven fabric, the menstrual blood easily clogs between the fibers, and the wearer feels sticky. Easily, and menstrual blood diffuses on the surface of the topsheet, making it easier to leak.

  In addition, a blood modifying agent having an IOB of about 0.00 to about 0.60 is highly organic and easily enters between blood cells, so that it stabilizes the blood cells and makes it difficult to form a monetary structure in the blood cells. It is considered possible. It is considered that the above-mentioned modifying agent stabilizes blood cells and makes it difficult to form a monetary structure on the blood cells, so that the absorbent body can easily absorb menstrual blood. For example, it is known that, in an absorbent article containing an acrylic superabsorbent polymer, so-called SAP, when menstrual blood is absorbed, the blood cells that have been collected cover the surface of the SAP, making it difficult for the SAP to exhibit absorption performance. It is considered that SAP stabilizes blood cells and can easily exhibit absorption performance. In addition, it is considered that the blood modifying agent having a high affinity for red blood cells protects the red blood cell membrane, so that the red blood cells are hardly destroyed.

Coating basis weight of the blood modifying agent to the top sheet 2 is preferably 1 to 30 g / m ^2, more preferably 3 to 10 g / m ^2. If the coating weight of the blood modifying agent is less than 1 g / m ² , it may be difficult to stably apply the blood modifying agent to the top sheet 2, and the coating weight of the blood modifying agent is 30 g / m ^2. If it is larger than m ² , the top sheet 2 may become slimy.

  The blood modifying agent is heated to a desired temperature and then applied to the top sheet 2 using a contact coater such as a slot coater, or a non-contact coater such as a spray coater, curtain coater, or spiral coater. Since the blood modifying agent in the form of droplets can be uniformly dispersed in the blood modifying agent application region 8 and the top sheet 2 is not damaged, the blood modifying agent is applied to the top sheet using a non-contact coater. 2 is preferably applied.

  When producing the nonwoven fabric for top sheets, a blood modifying agent may be applied to the nonwoven fabric. Further, the blood modifying agent may be applied to the top sheet 2 in the manufacturing process of the absorbent article 1. However, since the capital investment can be suppressed, it is preferable to apply the blood modifying agent to the top sheet 2 in the manufacturing process of the absorbent article 1. In addition, in order to prevent the blood modifying agent applied to the top sheet 2 from decreasing during the manufacturing process of the absorbent article 1, the blood modifying agent is applied to the top sheet in a process close to completion of the absorbent article 1. 2 is preferably applied. For example, the blood modifying agent may be applied to the top sheet 2 immediately before the step of packaging the absorbent article 1.

  FIG. 5 is a view for explaining the absorbent article 1 in which the wing portion 6 is folded for packaging. When packaging the absorbent article 1 having the above components, the pair of wing parts 6 are folded inward in the width direction as shown in FIG.

  The adhesive part 7 is covered with a release sheet 33. Thereby, the adhesion part 7 before use of the absorbent article 1 can be protected. The peeling sheet 33 will not be specifically limited if it is a sheet | seat which can peel with respect to the adhesive of the adhesion part 7. FIG. For the release sheet 33, for example, a release agent applied to a substrate can be used. Examples of the substrate on which the release agent is applied include films such as polypropylene, low density polyethylene, and polyvinyl alcohol, non-woven fabric, and paper. Examples of the release agent include silicone, fluorine, and isocyanate.

  As shown in FIG. 5, when the absorbent article 1 is packaged, the absorbent article 1 in which the wing portion 6 is folded is disposed on the packaging material 31. The packaging material 31 is a nonwoven fabric or a resin film, for example. A fastening tape 32 is provided at the longitudinal end of the packaging material 31. The absorbent article 1 arranged on the packaging material 31 is folded in the longitudinal direction (Y direction) along the BB line and the CC line together with the packaging material 31. Then, the fastening tape 32 is used to maintain the folded state of the absorbent article 1. And the both sides 31a of the width direction of the packaging material 31 folded together with the absorbent article 1 are joined by heat embossing. Thereby, the package 30 shown in FIG. 6 including the absorbent article 1 is produced. FIG. 6 is a perspective view of the packaged product 30 including the absorbent article.

  FIG. 7 is a schematic cross-sectional view showing a cross section along the line DD in FIG. As shown in FIG. 7, the side sheet 5 in the wing part 6 when the wing part 6 is folded contacts the blood modifying agent application region 18 (see FIG. 1) of the top sheet 2. Since the blood modifying agent is applied to the blood modifying agent application region 18, the top sheet 2 in the wing portion 6 comes into contact with the blood modifying agent. However, the protrusion 21 of the top sheet 2 reduces the contact area between the side sheet 5 and the blood modifying agent application region 18 of the top sheet 2 in the wing portion 6. Thereby, it can suppress that the blood modifier of the blood modifier application area | region 18 osmose | permeates the wing part 6, and the joint force between the top sheet 2 and the back sheet 3 in the wing part 6 weakens. Moreover, it can suppress that the blood modifier in the blood modifier application area | region 18 is transcribe | transferred by the side sheet 5 of the wing part 6, and the quantity of the blood modifier in the blood modifier application area | region 18 decreases.

  As described above, the fiber density of the central portion 23 of the protrusion 21 is lower than the fiber density of the side portion 24 and / or the recess 22 of the protrusion 21 (see FIG. 3). By the way, the blood modifying agent applied to the blood modifying agent application region 18 of the top sheet 2 tends to gather at a high fiber density of the top sheet 2. In the top sheet 2, the fiber density of the central portion 23 of the protrusion 21 that comes into contact with the wing portion 6 is lower than that of the side portion and the concave portion 22 of the protrusion 21. Not much drug is collected. Therefore, the amount of blood modifying agent transferred to the wing portion 6 is further reduced by lowering the fiber density of the central portion 23 of the protrusion 21 compared to the fiber density of the side 24 and / or the recess 22 of the protrusion 21. Can be made.

The absorbent article 1 according to the embodiment of the present invention can be modified as follows.
(1) An opening 26A may be formed in the recess 22A of the topsheet 2A as in the topsheet 2A shown in FIG. FIG. 8A is an enlarged perspective view of the protrusions, recesses and openings formed on the top sheet 2, and FIG. 8B is an enlargement of the protrusions, recesses and openings formed on the top sheet 2. FIG. The fiber density on the side surface of the opening 26A is preferably higher than the fiber density of the central portion 23A of the protrusion 21A. As a result, a large amount of blood modifying agent applied to the top sheet gathers around the opening 26A formed in the recess 22A, so that the blood modifying agent is not formed in the central portion 23 of the protrusion 21 that contacts the wing portion 6. I don't collect many drugs. Therefore, the amount of blood modifying agent transferred to the wing portion 6 when the wing portion 6 is folded is reduced by making the fiber density of the side surface of the opening 26A higher than the fiber density of the central portion 23A of the protrusion 21A. Can be made. Thereby, it can suppress that the side sheet | seat 5 which comprises the wing part 6 peels from the back sheet | seat 3 when the blood modifier applied to the top sheet 2A penetrate | invades into the wing part 6. FIG.

  For example, as shown in FIG. 9, the top sheet 2 </ b> A is provided by providing a net-like support member 130 with a plurality of elongated members 160 that extend in the width direction (CD) and are aligned in the machine direction (MD) and have no air permeability. An opening 26A can be formed in the recess 22A. In the portion where the elongated member 160 of the mesh-like support member 130 is not provided, the gas 141 injected from the blowing portion 140 passes through the mesh-like support member 130, so that the fibers of the web 120 can be formed so that the groove 122 can be formed in the web 120. Is scraped. On the other hand, in the portion where the elongated member 160 of the mesh support member 130 is provided, the gas 141 ejected from the blowing portion 140 does not pass through the mesh support member 130 and stops at the elongated member 160. The web 120 is scraped so strongly that an opening can be formed in the web 120. As a result, an opening 26A is formed in the recess 22A of the top sheet 2A. Since the scraped fibers are concentrated on the side surface of the opening 26A, the fiber density on the side surface of the opening 26A is increased.

(2) Like the top sheet 2B shown in FIG. 10, by projecting the nonwoven fabric constituting the top sheet 2B into a wave shape, the top sheet 2B extends in a predetermined direction and is aligned in a direction intersecting the predetermined direction. You may make it form 21B and the recessed part 22B. FIG. 10 is a schematic perspective view of a modified example of the top sheet. For example, by passing a nonwoven fabric between a pair of gear rolls, the top sheet 2B folded in a wave shape can be produced. Moreover, as shown in FIG. 11, you may form the opening part 26C in the recessed part 22C of the top sheet 2C which formed the protrusion 21C and the recessed part 22C by bending a nonwoven fabric into a wave shape.

  Fig.11 (a) is a schematic perspective view of the modification of a top sheet, FIG.11 (b) is a schematic plan view of the modification of a topsheet. For example, a protrusion roll having a plurality of protrusions in the shape of needles, cylinders, cones, etc. on the outer surface, and an anvil roll having a recess on the outer surface that fits the protrusions at positions corresponding to the protrusions of the protrusion roll By passing a non-woven fabric folded in a wave shape between the two, a top sheet in which an opening 26C is formed in the recess 22C can be produced. Since the opening 26C is formed by the protrusion of the protrusion roll passing through the nonwoven fabric, pressure is applied to the side surface of the opening 26C when the opening 26C is formed. Therefore, the fiber density on the side surface of the opening 26C is higher than the fiber density of the central portion 23C of the protrusion 21C. Accordingly, the blood modifying agent applied to the top sheet 2C collects on the side surface of the opening 26C of the recess 22C of the top sheet 2C, so that the amount of blood modifying agent transferred to the wing portion 6 when the wing portion 6 is folded. Can be reduced. Thereby, it can suppress that the side seat | sheet 5 which comprises the wing part 6 peels from the back sheet | seat 3 because the blood modifier applied to the top sheet 2C permeates the wing part 6.

(3) As shown in FIG. 12, the wing part 6 and the top sheet 2 when the wing part 6 is folded by forming the compression part 8D from the top sheet 2D to the inside of the absorber 4D in the absorbent article 1D. The area of contact with the blood modifying agent application region 18 may be reduced. 12 is a schematic cross-sectional view of an absorbent article 1D corresponding to the line AA in FIG. Thereby, when the wing part 6 is folded, the amount of the blood modifying agent transferred from the blood modifying agent application region 18 of the top sheet 2 to the wing part 6 can be reduced. The compression part 8D formed in the absorbent article 1D may be a linear compression part or a dotted compression part. The compression part 8D can be formed in the absorbent article 1D by, for example, embossing.

  Since the compression part 8D is formed by compressing the top sheet 2D and the absorbent body 4D in the thickness direction, the density of the top sheet 2D and the absorbent body 4D near the bottom of the compression part 8D is increased. For this reason, since the blood modifying agent applied to the top sheet 2D gathers toward the bottom of the compression unit 8D, when the wing unit 6 is folded, the blood modifying agent is applied from the blood modifying agent application region 18 of the top sheet 2 to the wing unit 6. It is possible to further reduce the amount of the blood modifying agent transferred to the blood. Thereby, it can suppress that the side sheet | seat 5 which comprises the wing part 6 peels from the back sheet | seat 3 because the blood modifier applied to the top sheet 2D permeates the wing part 6. In addition, when forming the compression part 8D, if the top sheet 2D of the compression part 8D is formed into a film, the blood modifying agent does not penetrate into the top sheet 2D. Therefore, the top sheet 2D in the compression part 8D is not formed into a film. Is preferred.

(4) If the contact area between the blood modifying agent application region 18 of the top sheet 2 and the wing portion 6 can be reduced, the protrusions formed in the blood modifying agent application region 18 of the top sheet 2 are not described above. It is not limited to the protrusion. For example, protrusions extending in the width direction (X direction) and aligned in the longitudinal direction (Y direction) may be provided in the blood modifying agent application region 18 of the top sheet 2. Further, a protrusion that extends in the longitudinal direction (Y direction) or the width direction (X direction) in a wavy form may be provided in the blood modifying agent application region 18 of the top sheet 2. Furthermore, a protrusion having a shape such as a cylinder, a prism, or a hemisphere may be provided in the blood modifying agent application region 18 of the top sheet 2.

(5) In order to further reduce the contact area between the blood modifying agent application region 18 of the top sheet 2 and the wing part 6, a protrusion may be formed on the side sheet 5. For example, like the absorbent article 1E shown in FIG. 13, the side sheet 5E may be provided with protrusions 51 extending in the longitudinal direction formed by bending in a wave shape. 13 is a schematic cross-sectional view of the absorbent article 1E corresponding to the line AA in FIG. If it can do, the protrusion formed in the blood modifying agent application region 18 of the top sheet 2 is not limited to the above-described protrusion. In addition, you may provide the protrusion extended in the width direction in a side seat | sheet. Moreover, you may provide the protrusion which extends in a longitudinal direction or the width direction with a wavy form in a side seat. Furthermore, a protrusion having a shape such as a cylinder, a prism, or a hemisphere may be provided on the side seat.

(6) The composition applied to the top sheet is not limited to the blood modifying agent as long as it is a predetermined composition. For example, a lotion that prevents rough skin may be applied to the top sheet.

  In the present invention, since the blood modifying agent has a mechanism for lowering the viscosity and surface tension of blood, the body fluid moves to the absorber 4 without remaining in the top sheet 2 by the blood modifying agent layer 24, and the absorber. 4 can be absorbed. The following examples confirmed that the blood modifying agent has a mechanism for lowering blood viscosity and surface tension.

[Example 1]
[Evaluation of rewetting rate and absorber transfer speed]
[Blood modifier data]
A commercially available sanitary napkin was prepared. The sanitary napkin includes a top sheet formed from an air-through nonwoven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 35 g / m ² ) treated with a hydrophilic agent, and an air-through nonwoven fabric (composite made of polyester and polyethylene terephthalate). Second sheet formed from fiber, basis weight: 30 g / m ² ), pulp (basis weight: 150 to 450 g / m ² , more in the center), acrylic superabsorbent polymer (basis weight: 15 g / m ² ) And an absorbent body containing a tissue as a core wrap, a side sheet treated with a water repellent, and a back sheet made of a polyethylene film.

The blood modifying agents used in the experiment are listed below.
[Ester of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid]
Unistar H-408BRS, manufactured by NOF Corporation Tetra-2-ethylhexanoate pentaerythritol, weight average molecular weight: about 640
Unistar H-2408BRS-22, manufactured by NOF Corporation Mixture of tetraerythritol tetra-2-ethylhexanoate and neopentyl glycol di-2-ethylhexanoate (58:42, weight ratio), weight average molecular weight: about 520

[Ester of (a ₂ ) chain hydrocarbon triol and at least one fatty acid]
· Cetiol SB45DEO, the Cognis Corp. fatty acids, oleic acid or stearic acid, triesters · SOY42 of glycerin and fatty acids, fatty acid manufactured by NOF Corporation C _14: fatty acid C _16: fatty acid C _18: Triester of glycerin and fatty acid, weight average molecular weight, containing C ₂₀ fatty acids (including both saturated and unsaturated fatty acids) in a weight ratio of approximately 0.2: 11: 88: 0.8 880

Tri-C2L oil fatty acid glyceride, manufactured by NOF Corporation C ₈ fatty acid: C ₁₀ fatty acid: C ₁₂ fatty acid containing approximately 37: 7: 56 weight ratio, glycerol and fatty acid triester, Weight average molecular weight: about 570
Tri-CL oil fatty acid glyceride, manufactured by NOF Corporation C ₈ fatty acid: Triester of glycerin and fatty acid containing fatty acid of C ₁₂ in a weight ratio of about 44:56, weight average molecular weight: about 570

· PANACET 810s, fatty acids manufactured by NOF Corporation C _8: fatty to C ₁₀ are contained in approximately 85:15 weight ratio of triesters of glycerol with fatty acids, the weight average molecular weight: about 480
・ Panasate 800, manufactured by NOF Corporation All fatty acids are octanoic acid (C ₈ ), triester of glycerin and fatty acid, weight average molecular weight: about 470

Panaceate 800B, manufactured by NOF Corporation All fatty acids are 2-ethylhexanoic acid (C ₈ ), triester of glycerin and fatty acid, weight average molecular weight: about 470
· NA36, manufactured by NOF Corporation C ₁₆ fatty acid: fatty acid C _18: (including both saturated and unsaturated fatty acids) fatty acids to C ₂₀ is approximately 5: contained in a weight ratio of 3: 92 Triester of glycerin and fatty acid, weight average molecular weight: about 880

· Tri-coconut oil fatty acid glyceride, NOF fatty Ltd. C _8: fatty C _10: fatty acid C _12: fatty acid C _14: (including both saturated and unsaturated fatty acids) fatty acids C ₁₆ is approximately 4 : Triester of glycerin and fatty acid, contained in a weight ratio of 8: 60: 25: 3, weight average molecular weight: 670
-Caprylic acid diglyceride, manufactured by NOF Corporation Fatty acid is octanoic acid, diester of glycerin and fatty acid, weight average molecular weight: 340

[Ester of (a ₃ ) chain hydrocarbon diol and at least one fatty acid]
-Compol BL, manufactured by NOF Corporation Butylene glycol dodecanoic acid (C ₁₂ ) monoester, weight average molecular weight: about 270
Compole BS, manufactured by NOF Corporation Butylene glycol octadecanoic acid (C ₁₈ ) monoester, weight average molecular weight: about 350
Unistar H-208BRS, NOF Corporation di-2-ethylhexanoic acid neopentyl glycol, weight average molecular weight: about 360

[(C ₂ ) an ester of a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or an oxo acid and at least one aliphatic monohydric alcohol]
・ Tributyl O-acetylcitrate, manufactured by Tokyo Chemical Industry Co., Ltd. Weight average molecular weight: about 400

[(C ₃ ) ester of a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or an oxo acid and at least one aliphatic monohydric alcohol]
・ Dioctyl adipate, manufactured by Wako Pure Chemical Industries, Ltd. Weight average molecular weight: about 380

[(D ₃ ) ester of fatty acid and aliphatic monohydric alcohol]
Electol WE20, an ester of dodecanoic acid (C ₁₂ ) and dodecyl alcohol (C ₁₂ ) manufactured by NOF Corporation, weight average molecular weight: about 360
Electol WE40, an ester of tetradecanoic acid (C ₁₄ ) and dodecyl alcohol (C ₁₂ ) manufactured by NOF Corporation, weight average molecular weight: about 390

[(E ₁ ) polyoxy C ₂ -C ₆ alkylene glycol]
・ Uniol D-1000, manufactured by NOF Corporation, polypropylene glycol, weight average molecular weight: about 1,000
-Uniol D-1200, manufactured by NOF Corporation, polypropylene glycol, weight average molecular weight: about 1,200
-Uniol D-3000, NOF Corporation polypropylene glycol, weight average molecular weight: about 3,000

・ Uniol D-4000, manufactured by NOF Corporation, polypropylene glycol, weight average molecular weight: about 4,000
・ Uniol PB500, polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 500
-Uniol PB700, manufactured by NOF Corporation polyoxybutylene polyoxypropylene glycol, weight average molecular weight: about 700

・ Uniol PB1000R, polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1000
[(E ₂ ) ester of polyoxy C ₂ -C ₆ alkylene glycol and at least one fatty acid]
-Wilbright cp9, manufactured by NOF Co., Ltd. A compound in which the OH groups at both ends of polybutylene glycol are esterified with hexadecanoic acid (C ₁₆ ), weight average molecular weight: about 1,150

[(E ₃ ) ether of polyoxy C ₂ -C ₆ alkylene glycol and at least one fatty acid]
Unilube MS-70K, NOF Corporation Polypropylene glycol stearyl ether, about 15 repeating units, weight average molecular weight: about 1,140

[(E ₅ ) ether of polyoxy C ₂ -C ₆ alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon diol]
・ Unilube 5TP-300KB
Polyoxyethylene polyoxypropylene pentaerythritol ether produced by adding 5 mol of ethylene oxide and 65 mol of propylene oxide to 1 mol of pentaerythritol, weight average molecular weight: 4,130

-Uniol TG-3000, manufactured by NOF Corporation Polyglycol glycol glyceryl ether, about 16 repeating units, weight average molecular weight: about 3,000
-Uniol TG-4000, manufactured by NOF Corporation Polyglycol glycol glyceryl ether, about 16 repeating units, weight average molecular weight: about 4,000

[(F ₁ ) chain alkane]
・ Pearl Ream 6, manufactured by NOF Corporation Branched hydrocarbons produced by copolymerizing liquid isoparaffin, isobutene and n-butene and then adding hydrogen, degree of polymerization: about 5 to about 10, weight average molecular weight : About 330

[Other materials]
-NA50, manufactured by NOF Corporation Hydrogen added to NA36 to reduce the ratio of double bonds derived from the unsaturated fatty acid as a raw material Triester of glycerin and fatty acid, weight average molecular weight: about 880
-(Caprylic acid / Capric acid) monoglyceride, NOF Corporation Octanoic acid (C ₈ ) and Decanoic acid (C ₁₀ ) in a weight ratio of approximately 85:15, monoester of glycerin and fatty acid, Weight average molecular weight: about 220
-Monomuls 90-L2 lauric acid monoglyceride, manufactured by Cognis Japan

・ Isopropyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd. Weight average molecular weight: about 230
・ Diisostearyl malate Weight average molecular weight: about 640
-Uniol D-400, manufactured by NOF Corporation, polypropylene glycol, weight average molecular weight: about 400

PEG 1500, manufactured by NOF Corporation, polyethylene glycol, weight average molecular weight: about 1,500 to about 1,600
Nonionic S-6, manufactured by NOF Corporation, polyoxyethylene monostearate, about 7 repeating units, weight average molecular weight: about 880
-Wilbright s753, NOF Corporation polyoxyethylene polyoxypropylene polyoxybutylene glycerin, weight average molecular weight: about 960

・ Uniol TG-330, manufactured by NOF Corporation Polypropylene glycol glyceryl ether, about 6 repeating units, weight average molecular weight: about 330
-Uniol TG-1000, manufactured by NOF Corporation Polyglycol glycol glyceryl ether, about 16 repeating units, weight average molecular weight: about 1,000

Unilube DGP-700, manufactured by NOF Corporation Polyglycol glycol diglyceryl ether, about 9 repeating units, weight average molecular weight: about 700
・ Uniox HC60, polyoxyethylene hydrogenated castor oil manufactured by NOF Corporation, weight average molecular weight: about 3,570
・ Vaseline, manufactured by Cognis Japan Co., Ltd. Petroleum-derived hydrocarbon, semi-solid

  The IOB, melting point and water solubility of the sample are shown in Table 2 below. The water solubility was measured according to the method described above, but 20.0 g was added to 100 g of demineralized water, and the sample dissolved after 24 hours was evaluated as “20 g <”, and the sample was dissolved in 100 g of demineralized water. , 0.05 g dissolved but 1.00 g not dissolved sample was evaluated as 0.05-1.00 g. Regarding the melting point, “<45” means that the melting point is less than 45 ° C.

The skin contact surface of the top sheet of the sanitary napkin was coated with the blood modifying agent described above. Each blood modifying agent is heated as it is if the blood modifying agent is liquid at room temperature, and if the blood modifying agent is solid at room temperature, it is heated to melting point + 20 ° C., and then control seam HMA gun Each blood modifying agent was atomized and applied to the entire skin contact surface of the top sheet so that the basis weight was approximately 5 g / m ² .

14 is an electron micrograph of the skin contact surface of the top sheet in a sanitary napkin (No. 2-5) in which the top sheet contains tri-C2L oil fatty acid glycerides. As is clear from FIG. 14, the tri-C2L oil fatty acid glyceride is in the form of fine particles and is attached to the surface of the fiber.
According to the above-mentioned procedure, the rewetting rate and the absorber transfer speed were measured. The results are shown in Table 2 below.

[Test method]
An acrylic plate with a hole (200 mm × 100 mm, 125 g, a hole of 40 mm × 10 mm is opened in the center) is placed on the top sheet containing each blood modifying agent, and 37 ± 1 ° C. from the hole. 3 g of equine EDTA blood (with equine blood added with ethylenediaminetetraacetic acid (hereinafter referred to as “EDTA”) to prevent coagulation) (1st time) using a pipette 3 g of equine EDTA blood at 37 ± 1 ° C. was dropped again with a pipette from the hole in the acrylic plate (second time).

Immediately after the second drop of blood, remove the acrylic plate immediately and place 10 pieces of filter paper (Qualitative Filter Paper No. 2, 50 mm x 35 mm) at the place where the blood was dropped. A weight was placed so as to be / cm ² . After 1 minute, the filter paper was taken out, and the “rewetting rate” was calculated according to the following formula.
Rewetting rate (%) = 100 × (filter paper mass after test−initial filter paper mass) / 6

In addition to the evaluation of the rewet rate, “absorber transfer rate”, which is the time for blood to transfer from the top sheet to the absorber, was measured after the second drop of blood. The above-mentioned absorption body transfer speed means the time from when blood is introduced into the top sheet until the redness of blood is not seen on the surface and inside of the top sheet.
The results of the rewet rate and the absorber transfer speed are shown in Table 2 below.

Subsequently, the whiteness of the skin contact surface of the top sheet after the test of the absorber transfer speed was visually evaluated according to the following criteria.
A: Almost no red blood remains, and it is not possible to distinguish between a place where blood is present and a place where blood does not exist. ○: Although a little red blood remains, It is difficult to distinguish the place where it does not exist. △: Some blood red remains, and the place where the blood existed. X: The blood red remains as it is. Show.

  In the absence of a blood modifying agent, the rewetting rate was 22.7% and the absorber transfer rate was more than 60 seconds, but all triesters of glycerin and fatty acids had a rewetting rate. Since it is 7.0% or less and the absorber transfer speed is 8 seconds or less, it can be seen that the absorption performance is greatly improved. However, among the triesters of glycerin and fatty acid, NA50 having a melting point exceeding 45 ° C. did not significantly improve the absorption performance.

  Similarly, a blood modifying agent having an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and a water solubility of about 0.00 to about 0.05 g for 100 g of water at 25 ° C. It was found that the absorption performance was greatly improved.

  Next, no. No. 2-1 to 2-47 sanitary napkins were worn by a plurality of volunteer subjects. In the sanitary napkin containing the blood modifying agents of 2-1 to 2-32, the top sheet was not sticky even after menstrual blood was absorbed, and the answer was that the top sheet was smooth. .

  No. 2-1. No. 2-32 sanitary napkins, and in particular, no. In the sanitary napkin containing the blood modifying agents of 2-1 to 11, 15 to 19 and 32, the skin contact surface of the top sheet after absorbing menstrual blood is not dyed red with blood, and there is little discomfort And got the answer.

[Example 2]
The rewetting rate was evaluated according to the procedure described above for various animal blood. The blood used in the experiment is as follows.
[Animal species]
(1) Human (2) Horse (3) Sheep

[Blood species]
・ Defibrinated blood: After collecting blood, stirred for about 5 minutes in an Erlenmeyer flask with glass beads ・ EDTA blood: 65 mL of venous blood plus 0.5 mL of 12% EDTA / 2K physiological saline

[Fractionation]
Serum or plasma: supernatant after centrifugation of defibrinated blood or EDTA blood at about 1900 G at room temperature for 10 minutes, respectively. Blood cell: serum is removed from the blood, and the residue is converted to phosphate buffered saline (PBS ) Washed twice and then added with phosphate buffered saline for the removed serum

An absorbent article was produced in the same manner as in Example 2 except that tri C2L oil fatty acid glyceride was applied so that the basis weight was approximately 5 g / m ² . . The measurement was performed 3 times for each blood, and the average value was adopted.
The results are shown in Table 3 below.

  Similar trends with equine EDTA blood obtained in Example 2 were also obtained with human and sheep blood. Similar trends were also observed in defibrinated blood and EDTA blood.

[Example 3]
[Evaluation of blood retention]
The blood retention in the top sheet containing the blood modifying agent and the top sheet not containing the blood modifying agent was evaluated.

[Test method]
(1) Tri C2L oil fatty acid glyceride was applied to the skin contact surface of the top sheet formed from an air-through nonwoven fabric (a composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g / m ² ) using a control seam HMA gun. It is atomized and applied so that the basis weight is approximately 5 g / m ² . Moreover, the thing which has not apply | coated the tri C2L oil fatty-acid glyceride is also prepared for a comparison. Next, both the top sheet coated with tri C2L oil fatty acid glyceride and the uncoated top sheet are cut to a size of 0.2 g, and the mass (a) of the cell strainer + top sheet is accurately determined. taking measurement.

(2) About 2 mL of horse EDTA blood is added from the skin contact surface side and allowed to stand for 1 minute.
(3) Place cell strainer in centrifuge tube and spin down to remove excess horse EDTA blood.
(4) The weight (b) of the top sheet containing the cell strainer + horse EDTA blood is measured.
(5) The initial absorption amount (g) per 1 g of the top sheet is calculated according to the following formula.
Initial absorption amount = [weight (b) −weight (a)] / 0.2
(6) The cell strainer is reset in the centrifuge tube and centrifuged at about 1200 G for 1 minute at room temperature.

(7) Measure weight (c) of top sheet containing cell strainer + horse EDTA blood.
(8) The post-test absorption amount (g) per 1 g of the top sheet is calculated according to the following formula.
Absorption after test = [weight (c) −weight (a)] / 0.2
(9) Blood retention (%) was calculated according to the following formula.
Blood retention rate (%) = 100 × absorption after test / initial absorption The measurement was performed three times and the average value was adopted. The results are shown in Table 4 below.

  It is suggested that the top sheet containing the blood modifying agent has low blood retention and can be rapidly transferred to the absorber after absorbing the blood.

[Example 4]
[Viscosity of blood containing blood modifying agents]
The viscosity of blood containing a blood modifying agent was measured using Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by mass of panacet 810s was added to equine defibrinated blood, and the sample was gently stirred to form a sample. . Because of the parallel plate, the sample did not have a uniform shear rate, but the average shear rate displayed on the instrument was 10 s ⁻¹ .

  The viscosity of equine defibrinated blood containing 2% by mass of panacet 810s was 5.9 mPa · s, while the viscosity of equine defibrinated blood containing no blood modifying agent was 50.4 mPa · s. Therefore, it can be seen that equine defibrinated blood containing 2% by mass of panacet 810s lowers the viscosity by about 90% compared to the case where no blood modifying agent is contained. Although blood is known to contain components such as blood cells and have thixotropic properties, the blood modifying agent of the present disclosure is considered to be able to lower the viscosity of blood in a low viscosity range. It is considered that the absorbed menstrual blood can be quickly transferred from the top sheet to the absorber by lowering the viscosity of the blood.

[Example 5]
[Micrograph of blood containing blood modifying agent]
A healthy volunteer's menstrual blood is collected on Saran Wrap (trademark), and a portion of panacet 810s dispersed in 10 times the mass of phosphate buffered saline is used, so that the concentration of panacet 810s is 1% by mass. Added to. Menstrual blood was appropriately applied to a slide glass, covered with a cover glass, and the state of red blood cells was observed with an optical microscope. A photomicrograph of menstrual blood containing no blood modifying agent is shown in FIG. 15 (a), and a photomicrograph of menstrual blood containing panacet 810s is shown in FIG. 15 (b).

  From FIG. 15, in menstrual blood that does not contain a blood modifying agent, red blood cells form a collective mass such as a remuneration, but in menstrual blood that includes panacet 810s, the red blood cells are each stably dispersed. I understand. Therefore, it is suggested that the blood modifying agent functions to stabilize red blood cells in the blood.

[Example 6]
[Surface tension of blood containing blood modifying agents]
The surface tension of blood containing a blood modifying agent was measured by a pendant drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd. The surface tension was measured after adding a predetermined amount of blood modifying agent to sheep defibrinated blood and shaking sufficiently. Although the measurement is automatically performed by the instrument, the surface tension γ is obtained by the following equation (see FIG. 16).

γ = g × ρ × (de) ² × 1 / H
g: Gravity constant 1 / H: Correction term obtained from ds / de ρ: Density de: Maximum diameter ds: Diameter at a position that is de higher than the dropping end

  The density ρ is defined in 5. of “Density Test Method and Density / Mass / Capacity Conversion Table” of JIS K 2249-1995. Based on the vibration density test method, the temperature was measured as shown in Table 5 below. For the measurement, DA-505 of Kyoto Electronics Industry Co., Ltd. was used. The results are shown in Table 5.

  From Table 5 it is clear that the blood modifying agent has a water solubility of about 0.00 to about 0.05 g in 100 g of water at 25 ° C. It can be seen that the surface tension of blood can be lowered. By reducing the surface tension of the blood, it is considered that the absorbed blood can be quickly transferred to the absorbent body without being held between the fibers of the top sheet.

  It is possible to combine one or a plurality of embodiments and modifications. It is also possible to combine modifications.

  The above description is merely an example, and the present invention is not limited to the above embodiment.

DESCRIPTION OF SYMBOLS 1,1D, 1E Absorbent article 2,2A-2D Top sheet 3 Back sheet 4,4D Absorber 5,5E Side sheet 6 Wing part 7 Adhesive part 8 Squeeze groove 8D Compression part 9 Seal part 10 Body part 16 Excretion mouthpiece Contact area 18 Blood modifying agent application area 21, 21A-C, 51E Protrusion 22, 22A-22C Recess 26A, 26C Opening 120 Web 121 Protrusion 122 Groove 130 Net-like support member 140 Blow-out part 150 Suction part 160 Elongated member

Claims (11)

The main body part has a longitudinal direction and a width direction, and includes a main body part and a pair of wing parts extending in the width direction from both side edges of the main body part, and the main body part is a liquid-permeable non-woven fabric provided on the skin side. An absorbent article comprising a top sheet, a liquid-impermeable back sheet provided on the clothing side, and a liquid-retaining absorbent provided between the top sheet and the back sheet,
The top sheet is provided with a protrusion in an excretion opening contact area that contacts at least the wearer's excretion opening on the skin side surface,
The top sheet further comprises a blood modifying agent placement region in which a blood modifying agent is placed at least in the excretory opening contact region ,
Wherein the blood modifying agent, that Yusuke and IOB of 0.00 to 0.60, and 45 ° C. The following melting, to water 100g of 25 ° C., and a water solubility of 0.00～0.05G,
The absorbent article. The projection extends in a direction Tokoro Sadakata, including projections and recesses arranged in a direction intersecting with the predetermined direction, the absorbent article according to claim 1. The absorbent article according to claim 2 , wherein the fiber density at the center of the protrusion is lower than the fiber density at the side of the protrusion and / or the fiber density of the recess. The concave portion of the top sheet has an opening,
The absorptive article according to claim 2 or 3 whose fiber density of the side of said opening is higher than the fiber density of the central part of said projection. The main body part has a longitudinal direction and a width direction, and includes a main body part and a pair of wing parts extending in the width direction from both side edges of the main body part, and the main body part is a liquid-permeable non-woven fabric provided on the skin side. An absorbent article comprising a top sheet, a liquid-impermeable back sheet provided on the clothing side, and a liquid-retaining absorbent provided between the top sheet and the back sheet,
A compression part formed by embossing from the top sheet to the inside of the absorber is provided in an excretion opening contact area that contacts at least a wearer's excretion opening on the skin side surface,
The top sheet comprises a blood modifying agent placement region in which a blood modifying agent is placed at least in the excretory opening contact region,
Wherein the blood modifying agent, that Yusuke and IOB of 0.00 to 0.60, and 45 ° C. The following melting, to water 100g of 25 ° C., and a water solubility of 0.00～0.05G,
The absorbent article. The blood modifying agent arrangement region is a range that is covered by the pair of wing portions when the pair of wing portions are folded inward in the width direction so that edges on the width direction outside of the pair of wing portions are in contact with each other The absorbent article of any one of Claims 1-5 provided in the inside. The absorbent article according to any one of claims 1 to 6 , wherein the wing portion has a protrusion on a skin-side surface. The blood modifying agent comprises the following (i) to (iii):
(I) hydrocarbons,
(Ii) from (ii-1) a hydrocarbon moiety and (ii-2) a carbonyl group (—CO—) and an oxy group (—O—) inserted between the C—C single bonds of the hydrocarbon moiety. A compound having one or more identical or different groups selected from the group consisting of: and (iii) (iii-1) a hydrocarbon moiety, and (iii-2) a CC single bond of said hydrocarbon moiety One or more of the same or different groups selected from the group consisting of a carbonyl group (—CO—) and an oxy group (—O—), inserted between them, and (iii-3) of the hydrocarbon moiety A compound having one or a plurality of the same or different groups selected from the group consisting of a carboxyl group (—COOH) and a hydroxyl group (—OH), which replaces a hydrogen atom;
As well as selected from the group consisting of any combination thereof,
Here, in the compound of (ii) or (iii), if the group is inserted more than one, each group are not adjacent, as claimed in any one of claims 1-7 Absorbent article. The blood modifying agent comprises the following (i ′) to (iii ′):
(I ′) hydrocarbon,
(Ii ′) (ii′-1) a hydrocarbon moiety and (ii′-2) a carbonyl bond (—CO—), an ester bond (—COO) inserted between the C—C single bonds of the hydrocarbon moiety. -), A carbonate bond (-OCOO-), and an ether bond (-O-), one or more compounds having the same or different bonds, and (iii ') (iii'- 1) a hydrocarbon moiety and (iii′-2) a carbonyl bond (—CO—), an ester bond (—COO—), a carbonate bond (—OCOO) inserted between the C—C single bonds of the hydrocarbon moiety. -), And one or a plurality of the same or different bonds selected from the group consisting of an ether bond (-O-) and (iii'-3) a carboxyl group that replaces a hydrogen atom of the hydrocarbon moiety ( -COOH ) And a hydroxyl group (—OH), one or more compounds having the same or different groups,
As well as selected from the group consisting of any combination thereof,
Here, in the compound of (ii ') or (iii'), when two or more identical or different bonds are inserted, each bond is not adjacent to any one of claims 1-8 Absorbent article as described in 1. The blood modifying agent comprises the following (A) to (F),
(A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain An ester with a compound having one carboxyl group for substituting a hydrogen atom in the hydrocarbon moiety,
(B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms in the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain An ether with a compound having one hydroxyl group replacing a hydrogen atom of the hydrocarbon moiety,
(C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a chain hydrocarbon moiety and 2 to 4 carboxyl groups that replace the hydrogen atoms of the chain hydrocarbon moiety; C2) an ester of a chain hydrocarbon moiety and a compound having one hydroxyl group replacing a hydrogen atom of the chain hydrocarbon moiety,
(D) an ether bond (—O—), a carbonyl bond (—CO—), an ester bond (—COO—) inserted between the chain hydrocarbon moiety and the C—C single bond of the chain hydrocarbon moiety. And a compound having any one bond selected from the group consisting of a carbonate bond (—OCOO—),
(E) polyoxy C ₂ -C ₆ alkylene glycol, or an alkyl ester or alkyl ether thereof, and (F) a chain hydrocarbon,
And it is selected from the group consisting of any combination thereof, the absorbent article according to any one of claims 1-9. The blood modifying agent comprises (a ₁ ) an ester of a chain hydrocarbon tetraol and at least one fatty acid, (a ₂ ) an ester of a chain hydrocarbon triol and at least one fatty acid, (a ₃ ) a chain An ester of a hydrocarbon diol and at least one fatty acid, (b ₁ ) an ether of a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, (b ₂ ) a chain hydrocarbon triol and at least one aliphatic Ethers with monohydric alcohols, (b ₃ ) ethers of chain hydrocarbon diols with at least one aliphatic monohydric alcohol, (c ₁ ) chain hydrocarbon tetracarboxylic acids having 4 carboxyl groups, hydroxy acids , alkoxy acid or oxo acid, at least one ester of an aliphatic monohydric alcohol, (c ₂₎ a chain hydrocarbon birds with 3 carboxyl groups Carboxylic acid, hydroxy acids, esters of alkoxy acids or oxoacids, and at least one aliphatic monohydric alcohol, (c ₃₎ a chain hydrocarbon dicarboxylic acids having two carboxyl groups, hydroxy acid, alkoxy acid or oxo An ester of an acid and at least one aliphatic monohydric alcohol, (d ₁ ) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, (d ₂ ) a dialkyl ketone, (d ₃ ) a fatty acid and an aliphatic 1 Esters with dihydric alcohols, (d ₄ ) dialkyl carbonates, (e ₁ ) polyoxy C ₂ -C ₆ alkylene glycols, (e ₂ ) esters of polyoxy C ₂ -C ₆ alkylene glycols with at least one fatty acid, (e ₃ ) polyoxy C ₂ -C ₆ alkylene glycol and at least one aliphatic monohydric ether alcohols, (e ₄ Polyoxy C ₂ -C ₆ alkylene glycol, an ester of a chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid, and (e ₅₎ polyoxy C ₂ -C ₆ alkylene glycol, A chain hydrocarbon tetraol, a chain hydrocarbon triol, or an ether with a chain hydrocarbon diol, and (f ₁ ) a chain alkane, and any combination thereof, selected from the group consisting of: The absorbent article according to any one of 10 .